Document:

Freestanding Dialysis Center Agreement No. 200308359

 Exhibit 10.8 
  

			
	

	  	CONFIDENTIAL TREATMENT

  
 AMENDMENT NO. 3
FREESTANDING DIALYSIS CENTER AGREEMENT NO. 200308359 
  
 The undersigned
hereby agree to amend Freestanding Dialysis Center Agreement No. 200308359 (the “Agreement”) between Amgen USA Inc. (“Amgen”), a wholly-owned subsidiary of Amgen Inc., and Gambro Healthcare, Inc. f/k/a Gambro Healthcare
Patient Services Inc. 10810 West Collins Avenue, Lakewood, Colorado, 80215 (“GAMBRO”), including any prior amendments thereto, as stated below. 
  
 WHEREAS, Amgen and GAMBRO entered into Freestanding Dialysis Center Agreement No. 200308359 effective January 1, 2004; 
  
 WHEREAS, the Agreement sets forth the terms and conditions for the purchase of
EPOGEN® (Epoetin alfa) and Aranesp® (darbepoetin alfa) (collectively, “Products”)
by GAMBRO, exclusively for the treatment of dialysis patients; and 
  
 WHEREAS, the parties wish to amend this Agreement to offer a [DELETED] for the period [DELETED], modify rebate programs for the period [DELETED] through [DELETED], and offer new rebates for the period [DELETED] through [DELETED].

  
 NOW, THEREFORE, in consideration of the premises and the mutual
promises and undertakings herein contained, the parties hereto agree as follows: 
  
 SECTION 1. Amendment and Restatement of the General Terms and Conditions – The General Terms and Conditions of the Agreement shall be amended and restated in their entirety effective as follows on December 1, 2004
provided GAMBRO executes this amended Agreement on or before December 1, 2004 (“Amended Date”). If GAMBRO executes this amended Agreement after December 1, 2004, the Amended Date shall be the date on which the party last to
execute this amended Agreement has executed this amended Agreement. 
  

	1.	Term of Agreement. The “Term” of this Agreement shall be defined as January 1, 2004 (“Commencement Date”) through December 31, 2005
(“Termination Date”). 

  

	2.	GAMBRO Affiliates. GAMBRO must provide Amgen with a complete list of its GAMBRO affiliates (“Affiliates”) on or before the date this Agreement is executed by
GAMBRO. Only those Affiliates approved by Amgen and listed on Appendix B hereto will be eligible to participate under this Agreement. Modifications to the list of Affiliates included in Appendix B may be made pursuant to the request of GAMBRO’s
corporate headquarters and are subject to approval and acknowledgment by Amgen in writing, which approval shall not be unreasonably withheld, conditioned or delayed. Notification of proposed changes to the list of Affiliates must be provided by
GAMBRO to Amgen in writing at least thirty (30) days before the effective date of the proposed change. Amgen reserves the right to accept, reject, or immediately terminate any Affiliates with regard to participation in this Agreement, which
right to accept, reject or terminate shall not be unreasonably exercised. 

  

	3.	Own Use. GAMBRO hereby certifies that Products purchased hereunder shall be for GAMBRO’s “own use” for the exclusive treatment of dialysis patients by GAMBRO
or its Affiliates. 

  

	4.	Pricing. See Appendix A. 

  

	5.	Authorized Wholesalers. On or before the date GAMBRO executes this Agreement, GAMBRO must provide Amgen with a complete list of its current wholesalers, including complete
names and addresses, from which GAMBRO intends to purchase Products. Wholesalers so designated by GAMBRO and approved by Amgen will be deemed “Authorized Wholesalers” for the purposes of this Agreement. A current list of GAMBRO’s
Authorized Wholesalers shall be included in Appendix C hereto. Notification of proposed changes to the list of Authorized Wholesalers must be provided by GAMBRO to Amgen in writing at least thirty (30) days before the effective date of the
proposed change. Amgen reserves the right to accept, reject, or immediately terminate any Authorized Wholesaler with regard to participation in this Agreement, which right to accept, reject or terminate shall not be unreasonably exercised. GAMBRO
agrees to require all Authorized Wholesalers to submit product sales information to a third-party sales reporting organization designated by Amgen. 

  
  
  
 [DELETED] = Portions of this exhibit are subject to a request for confidential treatment and have been redacted and filed separately with the Securities and Exchange
Commission. 
  

 - 1 - 

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

	6.	Qualified Purchases. Only Products purchased under this Agreement by GAMBRO from Amgen or through Authorized Wholesalers at the contract prices set forth herein, as confirmed
by Amgen based on sales tracking data, will be deemed “Qualified Purchases”. 

  

	7.	Commitment to Purchase. GAMBRO agrees to exclusively purchase Products for all of its dialysis use requirements for erythropoietic stimulating protein. GAMBRO may purchase
another brand of erythropoietic stimulating protein for its dialysis use requirements only if so ordered by a physician for the treatment of his or her dialysis patients and only for the time, and only to the extent, that Amgen has notified
GAMBRO’s corporate headquarters in writing that Amgen cannot supply EPOGEN® or
Aranesp® within and for the time period reasonably required by GAMBRO. Amgen will provide
GAMBRO with as much notice as reasonably possible in the event of an anticipated supply shortfall. 

  

	8.	Confidentiality. Both Amgen and GAMBRO agree that this Agreement represents and contains confidential information which shall not be disclosed to any third party, or
otherwise made public, without prior written authorization of the other party, except where such disclosure is contemplated hereunder or required by law, and then only upon prior written notification to the other party. 

  

	9.	Discounts. GAMBRO may qualify for discounts and incentives in accordance with the schedules and terms set forth in Appendix A hereto. Discounts in arrears will be paid in the
form of a check payable or wire transfer to GAMBRO’s corporate headquarters. Discounts in arrears will be calculated based on Qualified Purchases calculated using [DELETED], except as otherwise provided hereunder. Upon vesting of all earned
discounts, Amgen will use its best efforts to remit such discounts [DELETED] after receipt by Amgen of complete and machine readable data, in a form reasonably acceptable to Amgen, detailing all Qualified Purchases during the applicable period.
Discount amounts, as calculated by Amgen, must equal or exceed $500.00 for the applicable period to qualify for payment. Subject to Section 12 below, in the event that Amgen is notified in writing that GAMBRO or any Affiliates are acquired by
another entity or a change of control otherwise occurs with respect to GAMBRO or an Affiliate, any discounts which may have been earned hereunder shall be paid in the form of a check or wire transfer payable to GAMBRO’S or the Affiliate’s
corporate headquarters subject to the conditions described herein. If any Affiliates are added to or deleted from this Agreement during any of the comparison periods used in calculating any of the discounts paid in arrears contemplated herein, Amgen
reserves the right in its sole discretion to reasonably and appropriately adjust GAMBRO’s discounts for the relevant periods, by including or excluding any purchases made by those affected Affiliates during any of those relevant periods.

  

	10.	Treatment of Discounts. Amgen will provide GAMBRO with accurate documentation setting forth Amgen’s calculation of all discounts or reductions in price provided to
GAMBRO hereunder so as to permit GAMBRO to properly report any discount or reduction in price earned under this Agreement. GAMBRO agrees that it will properly disclose and account for any discount or other reduction in price earned hereunder,
in whatever form, (i.e. pricing, discount, or incentive) in a way that complies with all applicable federal, state, and local laws and regulations, including without limitation, Section 1128B(b) of the Social Security Act and its implementing
regulations. GAMBRO also agrees that it will (a) claim the benefit of such discount received, in whatever form, in the fiscal year in which such discount was earned or the year after, (b) fully and accurately report the value of such
discount in any cost reports filed under Title XVIII or Title XIX of the Social Security Act, or a state health care program, and (c) provide, upon request by the U.S. Department of Health and Human Services or a state agency or any other
federally funded state health care program, the information furnished by Amgen concerning the amount or value of such discount. GAMBRO’s corporate headquarters agrees that it will advise all Affiliates, in writing, of any discount received by
GAMBRO’s corporate headquarters hereunder with respect to purchases made by such Affiliates and that said Affiliates will account for any such discount in accordance with the above stated requirements. 

  

	11.	 Data Collection. GAMBRO agrees that all data to be provided to Amgen pursuant to this Agreement, shall be in a form that conforms with the limited data set
provisions of the Health Insurance Portability and Accountability Act of 1996 codified at 45 CFR 160 and 164 (“HIPAA”). GAMBRO acknowledges that the data to be supplied to Amgen pursuant to this Agreement shall be used to support
verification of the discounts and incentives referenced herein, as well as for Amgen-sponsored research concerning the role of EPOGEN® in improving treatment outcomes and quality of life of dialysis patients. GAMBRO shall consistently use a unique alpha-numeric code (which shall not be
the same as the patient’s social security number) as a “case identifier” to track the care rendered to each individual patient over time, and such case identifier shall be included in the data provided to Amgen. The key or list
matching patient identities to their unique case identifiers shall not be provided to 

  

					
	Amend No. 3 Agreement No. 200308359	 	- 2 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

	 	 
Amgen personnel. In furtherance of Amgen research, GAMBRO may agree from time to time to use its key to update the patient care data by linking it with
information concerning health outcomes, quality of life, and other pertinent data that may become available to Amgen from other sources. Any such linking of data sources shall not violate the limited data set provisions of HIPAA. Amgen agrees that
it will maintain data supplied under this Agreement in confidence and that it will not use such data to identify or contact any patient. 

  

	12.	Breach of Agreement. Either party may terminate this Agreement for failure of the other party to comply with any of the material obligations herein by serving upon the
defaulting party a written notice specifying the nature of the default and requiring such default to be cured. If such default is not cured [DELETED] from receipt of such notice, the notifying party shall be entitled, without prejudice to any of the
other rights conferred upon it by law or in equity, to terminate this Agreement in its entirety by giving written notice to the defaulting party to take effect immediately upon delivery of such notice. The right of either party to terminate this
Agreement shall not be affected in any way by its waiver or failure to take action with respect to any prior default. In addition, in the event that GAMBRO breaches any provision of this Agreement, Amgen shall have no obligation to continue to offer
the terms described herein or pay any further discounts to GAMBRO, other than discounts vested prior to the effective date of such termination. 

  

	13.	Governing Law. This Agreement shall be governed by the laws of the State of California and the parties submit to the jurisdiction of the California courts, both state and
federal. 

  

	14.	Warranties. Each party represents and warrants to the other that this Agreement (a) has been duly authorized, executed, and delivered by it, (b) constitutes a
valid, legal, and binding agreement enforceable against it in accordance with the terms contained herein, and (c) does not conflict with or violate any of its other contractual obligations, expressed or implied, to which it is a party or by
which it may be bound. The party executing this Agreement on behalf of GAMBRO specifically warrants and represents to Amgen that it is authorized to execute this Agreement on behalf of and has the power to bind GAMBRO and the Affiliates to the terms
set forth in this Agreement. The party executing this Agreement on behalf of Amgen specifically warrants and represents to GAMBRO that it is authorized to execute this Agreement on behalf of and has the power to bind Amgen to the terms set forth in
this Agreement. 

  

	15.	Notices. Any notice required or permitted to be given under this Agreement shall be deemed to be duly given if in writing and personally delivered by messenger, facsimile
transmission (receipt verified and confirmed by overnight mail), express courier service or overnight mail (requiring signature receipt) or by prepaid, registered or certified mail (postage prepaid, return receipt requested), addressed to the
respective parties for whom such notice is intended as stated below, or to such changed address as such party may have fixed by notice: 

  

			
	If to Amgen:	  	 Amgen USA Inc.
 One Amgen Center Drive
 Thousand Oaks, California 91320-1789
 Attention: General Counsel
 Facsimile: (805) 499-8011

		
	If to GAMBRO:	  	 Gambro Healthcare, Inc.
 10810 W. Collins
Avenue
 Lakewood, CO 80215
 Attention: General
Counsel

		
	 	  	And
		
	 	  	 Gambro Healthcare, Inc.
 15253 Bake Pkwy
 Irvine, CA 92618
 Attention: Terry Lindsay
 Senior Vice President
 Purchasing and Materials Management
 Facsimile: 949-930-6958

  

					
	Amend No. 3 Agreement No. 200308359	 	- 3 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

 All notices given pursuant to this Section 15 shall be deemed given and effective when received if personally
delivered or sent by facsimile or similar form of communication, or, if mailed, on the date shown on the return receipt, or, if a receipt has not then been received, five (5) days after mailing, or, if sent by overnight courier, on the date
shown for receipt on the courier’s records. 
  

	16.	Compliance with Health Care Pricing and Patient Privacy Legislation and Statutes; Data Use Agreement. 

  
 (a) Notwithstanding anything contained herein to the contrary, at any time
following the enactment of any federal, state, or local law, regulation, policy, program memorandum or other interpretation, modification or utilization guideline by any payer that in any manner reforms, modifies, alters, restricts, or otherwise
affects the pricing of or reimbursement available for the Products, including but not limited to a reimbursement or use decision by Centers for Medicare and Medicaid Services (“CMS”) or one of its contractors (Carriers or Fiscal
Intermediaries), Amgen may, in its sole discretion, upon thirty (30) days notice, (1) terminate this Agreement, (2) modify any pricing or discount terms contained herein, or (3) exclude any Affiliate from participating in this
Agreement. Without limiting the foregoing, any change, modification or further clarification to the Medicare Modernization Act or any rules or regulations promulgated thereunder, or the Hematocrit Measurement Audit Program Memorandum that occurs
subsequent to the Amended Date would specifically trigger the right to the termination or modification referenced herein. Additionally, to assure compliance with any existing federal, state or local statute, regulation or ordinance, Amgen reserves
the right, in its sole discretion, to exclude any Affiliates from the pricing and discount provisions of this Agreement and/or to reasonably modify any pricing or discount terms contained herein. In the event there is a future change in Medicare,
Medicaid, or other federal or state statute(s) or regulation(s) or in the interpretation thereof, which renders any of the material terms of this Agreement unlawful or unenforceable, this Agreement shall continue only if amended by the parties as a
result of good faith negotiations as necessary to bring the Agreement into compliance with such statute or regulation. 
  
 (b) Notwithstanding anything contained herein to the contrary, at any time following the enactment of any federal, state, or local law or regulation
relating to patient privacy of medical records that in any manner reforms, modifies, alters, restricts, or otherwise affects any of the data received or to be received in connection with any of the incentives contemplated under this Agreement,
either party may, in its discretion, upon thirty (30) days’ notice, seek to modify this Agreement with respect to the affected incentive. GAMBRO and Amgen shall meet and in good faith seek to mutually agree to modify this Agreement to
accommodate any such change in law or regulation, with the intent to, if possible, retain the essential terms and pricing structure of the affected incentive. If the parties, after reasonable time, are unable to agree upon a modification, Amgen
shall be entitled to terminate the affected incentive upon thirty (30) days’ notice or upon such date that the law or regulation requires, whichever is earlier. 
  
 (c) Notwithstanding anything contained herein to the contrary, this Agreement is effective only as of the date the parties
hereto execute a mutually agreeable Data Use Agreement pursuant to which GAMBRO may disclose a Limited Data Set of patient information to Amgen (as specified in the Data Use Agreement and which shall include, at a minimum, the data fields to be
received by Amgen in connection with this Agreement) for purposes of Amgen’s Healthcare Operations, Research, and Public Health analyses, and GAMBRO’s Healthcare Operations. Unless otherwise specifically defined in this Agreement, each
capitalized term used in this Section 16(c) shall have the meaning assigned to such term in the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). If GAMBRO terminates the Data Use Agreement for any reason, Amgen
shall be entitled to terminate this Agreement immediately. 
  

	17.	Force Majeure. Neither party will be liable for delays in performance or nonperformance of this Agreement or any covenant contained herein if such delay or nonperformance is
a result of Acts of God, civil or military authority, civil disobedience, epidemics, terrorism, war, failure of carriers to furnish transportation, strike, lockout or other labor disturbances, inability to obtain material or equipment, or any other
cause of like or different nature beyond the control of such party. 

  

	18.	 Miscellaneous. No modification of this Agreement will be effective unless mutually agreed upon, made in writing and executed by a duly authorized
representative of each party, except as otherwise provided hereunder. Neither party may assign this Agreement to a third party without the prior written consent of the other party; provided, however, that Amgen may 

  

					
	Amend No. 3 Agreement No. 200308359	 	- 4 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

	 	 
assign this Agreement to any of its subsidiaries or affiliates without the consent of GAMBRO. This Agreement may be executed in one or more counterparts,
each of which is deemed to be an original but all of which taken together constitutes one and the same agreement. In the event that the [DELETED], Amgen and GAMBRO will agree [DELETED]. Amgen reserves the right to rescind this offer if the parties
fail to execute this Agreement within thirty (30) days from the date of its offering. 

  
 Beginning [DELETED], GAMBRO’s aggregate Qualified Purchases of Products by all Affiliates listed on Appendix B on the Amended Date of this Agreement
during any [DELETED] of this Agreement shall not exceed [DELETED] of the aggregate Qualified Purchases of Products by those same Affiliates for the [DELETED]. GAMBRO shall not be eligible to receive any rebates detailed in Appendix A of this
Agreement for any Qualified Purchases of Products in the aggregate made during any [DELETED] of this Agreement that exceed [DELETED] of the aggregate Qualified Purchases of Products by those same Affiliates in the [DELETED]. Any of GAMBRO’s
aggregate Qualified Purchases of Products above [DELETED] of the aggregate Qualified Purchases of Products by those same Affiliates in the [DELETED] may be approved and eligible to receive rebates detailed in Appendix A if Amgen, in its sole
discretion, determines that such [DELETED]. Amgen shall make such determination based upon a review of all relevant reports including, but not limited to: [DELETED]. Such determination must be approved by Amgen’s [DELETED] Senior Management.
For purposes of determining the foregoing, during the period [DELETED], Products base sales during each [DELETED] shall be derived using the [DELETED]. 
  

	19.	Entire Agreement. This Agreement constitutes the entire understanding between the parties and supersedes all prior written or oral proposals, agreements, or commitments
pertaining to the subject matter herein. 

  

	20.	Right of First Offer. GAMBRO shall promptly notify Amgen in the event it receives a competing offer from any third party for the sale of products in the same therapeutic
class. Amgen shall have the right in such event to have [DELETED] days to respond to GAMBRO with its own pricing terms relating to products. 

  

	21.	[DELETED] 

  

					
	Amend No. 3 Agreement No. 200308359	 	- 5 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

 Please retain one fully executed original for your records and return the other fully executed original to Amgen.

  
 The parties agree that each shall execute this Agreement by counterpart
signature pages each of which when taken together shall constitute the entire Agreement. 
  
 The parties executed this amendment and restatement of the Agreement as of the dates set forth below. 
  

									
	Amgen USA Inc.	 	 	 	Gambro Healthcare, Inc.
					
	Signature:	 	 /s/ Christy Mc Elroy
	 	 	 	Signature:	 	 /s/ Terry Lindsay

					
	Print Name:	 	 Christy Mc Elroy
	 	 	 	Print Name:	 	 Terry Lindsay

					
	Print Title:	 	 Associate Dir Nat. Accts.
	 	 	 	Print Title:	 	 SVP

					
	Date:	 	 11/24/04
	 	 	 	Date:	 	 11/24/04

					
	Signature:	 	 /s/ Leslie Mirani
	 	 	 	Signature:	 	 /s/ James H. Booth

					
	Print Name:	 	 Leslie Mirani
	 	 	 	Print Name:	 	 James H. Booth

					
	Print Title:	 	 Jr. Dir. Sales Nephrology
	 	 	 	Print Title:	 	 COO Support Services

					
	Date:	 	 12/2/04
	 	 	 	Date:	 	 12/3/04

					
	 	 	 	 	 	 	Signature:	 	 /s/ Larry C. Buckelew

					
	 	 	 	 	 	 	Print Name:	 	 Larry C. Buckelew

					
	 	 	 	 	 	 	Print Title:	 	 President/CEO

					
	 	 	 	 	 	 	Date:	 	 12/02/04

  

					
	Amend No. 3 Agreement No. 200308359	 	- 6 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

 SECTION 2. Amendment and Restatement of Appendix A: Discount Pricing, Schedule and Terms.
Appendix A: Discount Pricing, Schedule and Terms shall be amended and restated in its entirety to modify the [DELETED] for the period [DELETED] through [DELETED], modify the rebate programs for the period [DELETED] through [DELETED], offer a
[DELETED] for the period [DELETED] through [DELETED], and offer a [DELETED] for the period [DELETED] through [DELETED] effective on the Amended Date as follows. 
  
 Appendix A: Discount Pricing, Schedule, and Terms 
  

	1.	Pricing – Aranesp®. GAMBRO may purchase Aranesp® (darbepoetin) through Authorized Wholesalers at a fixed [DELETED] during the Term. Amgen reserves the right to change the [DELETED] at any time. Resulting prices do not include any
wholesaler markup, service fees, or other charges. No other discounts, including discounts in arrears, are applicable to Aranesp® purchased under this Agreement 

  

	2.	Pricing – EPOGEN®. GAMBRO may purchase EPOGEN® (Epoetin alfa) during the Term through Authorized Wholesalers at the prevailing [DELETED]. Amgen reserves the right to change the [DELETED] at any time. In the event that an increase in
the [DELETED] is effectuated during the Term of this Agreement, GAMBRO’s price (excluding any discount in arrears) for Qualified Purchases of EPOGEN® shall [DELETED]. For purposes of calculating all discounts in arrears earned during the [DELETED], Qualifying Purchases shall be calculated
based upon the [DELETED], such that any [DELETED] contained in any of the discounts or incentives set forth in this Appendix A shall [DELETED] in the [DELETED]. 

  

	3.	Rebate/Incentive Qualification Requirements. 

  
 (a) [DELETED]: In order for GAMBRO to be eligible to receive any rebates or incentives described in [DELETED] of this Appendix A, GAMBRO must satisfy the
following qualification requirement. No more than [DELETED] of GAMBRO’s [DELETED] may have [DELETED] (as that term is defined below) [DELETED] during each [DELETED] during the Term of this Agreement (“[DELETED] Requirement”). If this
criteria is not met during any [DELETED] of the Term of the Agreement, GAMBRO will not qualify for any rebates in [DELETED] of this Appendix A during that [DELETED]. Failure of GAMBRO to qualify under this provision during a particular [DELETED]
shall not affect GAMBRO’s eligibility to qualify during any other [DELETED] of the Term, nor shall GAMBRO’s qualification during a particular [DELETED] automatically result in qualification during any other [DELETED]. The [DELETED] for
each dialysis patient will be based upon the average of [DELETED] for each patient during each [DELETED]. GAMBRO and Affiliates must provide the following information for each dialysis patient to Amgen or to a data collection vendor specified by
Amgen, on a [DELETED] basis, and no later than [DELETED] after the end of each [DELETED]: [DELETED] for each dialysis patient, the date of each test, and a consistent, unique, alpha-numeric identifier (sufficient consistently to track an individual
patient without in any way violating the de-identification provisions of HIPAA at 45 CFR 164.514), a designation as to which patients are “Prevalent Dialysis Patients” (for purposes of this Agreement, Prevalent Dialysis Patients shall be
defined as those patients who have been receiving dialysis treatments from GAMBRO for fifteen (15) days or more), along with the name, address and phone number of the particular Affiliate at which each patient received treatment. To the extent
permitted by applicable law, Amgen may utilize the data detailed in this provision for any purpose, and reserves the right to audit all such data. Under no circumstances should such data include any patient identifiable information including,
without limitation, name, all or part of social security number, address, medical record number, or prescription number. The identity of the account submitting the data and any association with the data will remain confidential. The [DELETED] must
be derived from [DELETED] taken immediately before dialysis treatment using any [DELETED] testing method (e.g. [DELETED]), must be reported to the [DELETED], and must be submitted [DELETED] in a format acceptable to Amgen. Handwritten reports are
not acceptable; only machine readable submission of the data will be accepted; and 
  
 (b) [DELETED]: In order for GAMBRO to be eligible to receive any rebates or incentives described in [DELETED] of this Appendix A, GAMBRO must satisfy the following qualification requirement. GAMBRO’s aggregate
Qualified Purchases of EPOGEN® and Aranesp® during [DELETED], and during [DELETED] by all
Affiliates listed on Appendix B on the Commencement Date of this Agreement and those added at the beginning of [DELETED] must equal or exceed [DELETED] and [DELETED] respectively ([DELETED]), of the aggregate Qualified Purchases of EPOGEN® and Aranesp® by those same Affiliates for the time period from [DELETED], and from [DELETED]. For
purposes of calculating the [DELETED], EPOGEN® and
Aranesp® base sales during each applicable time
period shall be derived using the [DELETED]. All estimated payments for discounts in arrears that contain [DELETED] will be measured by using a [DELETED] that measures [DELETED]. If 

  

					
	Amend No. 3 Agreement No. 200308359	 	- 7 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

	 	 
GAMBRO has not satisfied the [DELETED] for any particular [DELETED], then at the end of the following [DELETED], beginning with [DELETED], Amgen will
determine if GAMBRO has satisfied, in the aggregate, on a [DELETED] basis, the [DELETED]. If the [DELETED] has been met for that given [DELETED], then Amgen will perform a [DELETED] calculation for [DELETED]. However, if at the end of [DELETED] the
[DELETED], Amgen will perform a [DELETED], which may [DELETED]. The [DELETED] payments and any other discount or incentive earned in arrears corresponding to the [DELETED], respectively if any, shall not be due and owing by Amgen until, and shall be
subject to, such [DELETED]. [DELETED] will be made [DELETED], within [DELETED] days after the [DELETED] and receipt by Amgen of all the required data detailed in this Agreement. The determination as to GAMBRO’s attainment or failure to attain
the [DELETED] shall be based upon [DELETED]. 

  

	4.	[DELETED]. GAMBRO may qualify for the [DELETED] ([DELETED]) during each [DELETED] Measurement Period (as defined in the schedule below) as described in this Section 4 of
Appendix A. 

  
 [DELETED] Measurement Periods

 [DELETED] 
  
 [DELETED] 
  
 [DELETED] 
  
 [DELETED] 
  
 (a) Requirement: In order to
qualify for the [DELETED] GAMBRO must meet the [DELETED] Requirement contained in [DELETED] of this Appendix A. If this criteria is not met during any [DELETED] during the period [DELETED], GAMBRO will not qualify for [DELETED] described below in
this Section 4 during that [DELETED]. Failure of GAMBRO to qualify under this provision during a particular [DELETED] shall not affect GAMBRO’s eligibility to qualify during any other [DELETED] during the period [DELETED], nor shall
GAMBRO’s qualification during a particular [DELETED] automatically result in qualification during any other [DELETED]. 
  
 (b) Calculation: GAMBRO’s [DELETED] will be calculated in accordance with the following formula and the [DELETED] Schedule listed below.
[DELETED] will be calculated on a [DELETED] basis. 
  
 [DELETED]
= A x B 
  
 where: 
  

	 	A = 	[DELETED] during the period [DELETED] by all Affiliates in the [DELETED] in which the requirements under [DELETED] this Appendix A are met. 

  

	 	B = 	A percent in accordance with the [DELETED] Schedule listed below. 

  

	 	C = 	[DELETED] during the applicable [DELETED] by all Affiliates as listed on Appendix B [DELETED]. 

  

	 	D = 	[DELETED] by those same Affiliates as listed on Appendix B [DELETED] during the period [DELETED] using the [DELETED] of this Agreement in accordance with the [DELETED]:

  

			
	 Measurement Period

	  	 [DELETED] Schedule

	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]

  

					
	Amend No. 3 Agreement No. 200308359	 	- 8 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

 (c) [DELETED] Schedule. The [DELETED] schedule is as follows: 
  

			
	 [DELETED]

	  	 B

	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]

  
 (d) Payment.
Estimated payments will be made [DELETED] within [DELETED] days using Amgen’s discount calculation schedules, and the [DELETED] after receipt by Amgen of [DELETED]. 
  
 (e) Vesting. GAMBRO’s [DELETED] will vest [DELETED]. In the event the estimated [DELETED] payments paid to
GAMBRO each [DELETED] exceed GAMBRO’s actual [DELETED], GAMBRO shall reimburse Amgen the difference between the [DELETED] payment paid and the [DELETED] payment amount earned within [DELETED] days of GAMBRO’s receipt of Amgen’s
written notification of such difference. 
  

	5.	[DELETED]. For the Term of the Agreement GAMBRO shall be eligible to receive a [DELETED] provided that certain data elements specified below are transmitted to Amgen electronically.
GAMBRO will use its best efforts that are reasonably available and recorded. The [DELETED] will be calculated as a percentage of the Qualified Purchases of EPOGEN® attributable to GAMBRO during each [DELETED]. To qualify for the [DELETED] the following [DELETED] must be submitted to
Amgen by GAMBRO and all Affiliates in a machine readable format acceptable to Amgen (Excel; Lotus 123.wk1; or text file that is tab delimited, comma delimited, colon delimited or space delimited): 

  
 Facility ID; 
 Patient ID (sufficient to consistently track an individual patient without in any way disclosing the identity of the patient); 
 [DELETED]; 
 [DELETED]; 
  
 Modality; Hemodialysis (“HD”) ID or peritoneal dialysis
(“PD”) ID (a PD patient shall be defined as a patient who receives at least one (1) peritoneal dialysis treatment during a given month as recorded in data base) – [DELETED]; 
 [DELETED] with date [DELETED]; 
 All [DELETED]
with their corresponding draw dates for each patient by Patient ID; 
 [DELETED] delivered for each patient per treatment with date;

 [DELETED]; 
 [DELETED];

 [DELETED]; 
 [DELETED];

  
 [DELETED] with date for peritoneal dialysis patients only;

  
 [DELETED]; 
 [DELETED]; and 
 [DELETED] 
  

					
	Amend No. 3 Agreement No. 200308359	 	- 9 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

 (a) For the period [DELETED], the following [DELETED] shall be added as requirements of the
[DELETED]. Data submission of the following patient data for the period [DELETED] and for the period [DELETED] shall be no later than [DELETED]. 
  
 [DELETED]; 
 [DELETED]; 
 [DELETED]; 
 [DELETED]; 
 [DELETED] 
  
 (b) For the period [DELETED], the following [DELETED] shall be removed as requirements of the [DELETED]: 
  
 [DELETED] 
  
 Such patient data must be submitted, on a [DELETED] basis, and no later than [DELETED] days after the end of each [DELETED].
If such patient data is received more than [DELETED] days after the last day of any [DELETED] within a given [DELETED], the total Qualified Purchases of EPOGEN® attributable to GAMBRO during such [DELETED] will be excluded from the calculation of the [DELETED] for that [DELETED].
Notwithstanding the foregoing, if Amgen receives all required data from a minimum of [DELETED] of all Affiliates within the time frame referenced above for any [DELETED] within a given [DELETED], the total Qualified Purchases of EPOGEN® attributable to GAMBRO and all Affiliates during such
[DELETED], will be included in the calculation of the [DELETED] for that [DELETED]. However, if Amgen determines that any Affiliate is consistently not submitting the required data, Amgen and GAMBRO will work collaboratively in resolving such
inconsistencies. Amgen reserves the right, in its sole discretion, to exclude any such non-reporting Affiliate’s Qualified Purchases of EPOGEN® from the calculation of the [DELETED] for any relevant [DELETED]. All data to be submitted by GAMBRO to Amgen must include a designation as to which
patients are “Prevalent Dialysis Patients” (for purposes of this Agreement, Prevalent Dialysis Patients shall be defined as those patients who have been receiving dialysis treatments from GAMBRO for fifteen (15) days or more). 

 
 The [DELETED] will vest [DELETED] on the last day of [DELETED]
respectively, and be paid [DELETED] in accordance with the terms and conditions described in Section 9 of the Agreement. 
  

	6.	[DELETED]. The purpose of the [DELETED] is to [DELETED] from GAMBRO and its Affiliates and received by Amgen, such that the [DELETED] used by both companies are [DELETED]. For the
period [DELETED] GAMBRO shall be eligible to receive a [DELETED] provided the following requirements are met. The [DELETED] will be calculated as a percentage of the Qualified Purchases of EPOGEN® attributable to GAMBRO during each [DELETED]. 

  
 (a) To qualify for the [DELETED], the following requirements must be met: 
  

	 	i)	GAMBRO must submit, each [DELETED], in a machine readable format acceptable to Amgen (Excel; Lotus 123.wk1; or text file that is tab delimited, comma delimited, colon delimited or
space delimited), all identifying information for a facility (e.g. GAMBRO’s account hierarchy for each facility submitted) (the “Facility Reference File”). The Amgen ACIS # must be included in the Facility Reference File for any
[DELETED] submissions made on or after [DELETED]; 

  

	 	ii)	GAMBRO must notify Amgen no later than [DELETED] days prior to implementing any [DELETED] in the [DELETED] made by GAMBRO and its Affiliates to Amgen under this Agreement and Amgen
may reasonably request modifications to such [DELETED] to ensure [DELETED] of the such [DELETED]. 

  
 (b) To qualify for the [DELETED], the following additional requirements must be met: 
  

	 	i)	GAMBRO must develop, in conjunction with Amgen, and deliver on or prior to [DELETED], a mutually agreeable [DELETED] following an [DELETED] by GAMBRO and/or [DELETED] GAMBRO
[DELETED]; 

  

	 	ii)	 GAMBRO and Amgen must mutually agree upon in detail a [DELETED] intended to develop and improve the [DELETED] GAMBRO and Amgen (the “[DELETED]”). The
[DELETED] must be detailed, set forth in writing and attached as an addendum to the contract on or before [DELETED]. The [DELETED] must include detailed [DELETED] on a specific timeline for the period [DELETED]. These [DELETED] and timeline
[DELETED] will be used to determine the 

  

					
	Amend No. 3 Agreement No. 200308359	 	- 10 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

	 	 
[DELETED] requirements for earning the [DELETED] for the period [DELETED]. The [DELETED] should include the following as well as other mutually agreed upon
[DELETED]: 

  

	 	•	 	[DELETED] to discuss the [DELETED] of each project, with additional [DELETED] as required; 

  

	 	•	 	Develop and deliver a [DELETED] for [DELETED] to include [DELETED] 

  

	 	•	 	Define [DELETED]; 

  

	 	•	 	Develop and deliver a [DELETED]; 

  

	 	•	 	Develop and deliver a [DELETED]; 

  

	 	•	 	Develop and deliver a [DELETED]. 

  

	 	•	 	Develop and deliver a [DELETED] at initial dialysis data for inclusion in the data, if feasible, required to be submitted in Appendix A Section 5. 

  
 (c) To qualify for the [DELETED] for the period [DELETED], GAMBRO must
additionally achieve the [DELETED] goals as set forth in the [DELETED]. 
  
 The Facility Reference File referenced in this Section 6(a)(i) must be submitted, on a [DELETED] basis, and no later than [DELETED] after the end of each [DELETED]. If such Facility Reference File is received
more than [DELETED] days after the last day of any [DELETED] within a given [DELETED], the total Qualified Purchases of EPOGEN® attributable to GAMBRO during such [DELETED] will be excluded from the calculation of the [DELETED] for that [DELETED]. 
  
 The [DELETED] will vest [DELETED] on the [DELETED] of [DELETED] and be paid
[DELETED] in accordance with the terms and conditions described in Section 9 of the Agreement. 
  

	7.	[DELETED]. For the Term of the Agreement, GAMBRO may qualify for the [DELETED] (“[DELETED]”) provided it meets the criteria described below in this Section 7. The
[DELETED] is designed to improve patient outcomes by encouraging [DELETED]. 

  
 (a) Requirements: In order to qualify for the [DELETED], GAMBRO must meet the [DELETED] of this Appendix A, and GAMBRO and its Affiliates must provide Amgen the following data items, on a [DELETED] basis, and
no later than [DELETED] days after the end of each [DELETED], in a machine readable format acceptable to Amgen (Excel; Lotus 123.wk1; or text file that is tab delimited, comma delimited, colon delimited or space delimited) in accordance with the
data submission requirements contained in Section 5 of this Appendix A for [DELETED] and date, AND [DELETED] with date for each patient by GAMBRO and its Affiliates. In the event [DELETED] is submitted, instead of [DELETED], Amgen will convert
such [DELETED] values to [DELETED] values by [DELETED]. Amgen will convert all lab values taken of [DELETED] for each patient by GAMBRO and its Affiliates, AND all the lab values taken of [DELETED] for each patient by GAMBRO and its Affiliates into
the [DELETED] for each patient by GAMBRO and its Affiliates, AND the [DELETED] for each patient by GAMBRO and its Affiliates for each of the [DELETED] Measurement Periods (as defined in the schedule immediately below). GAMBRO hereby certifies that
the data submitted for each eligible Affiliate includes the required results from all dialysis patients of such Affiliate, and does not include results from non-patients. GAMBRO also represents and warrants that it (i) has no reason to believe
that the submitted data is incorrect, and (ii) is or will be authorized to make this certification on behalf of all eligible Affiliates when submitting data. 
  
 [DELETED] Measurement Periods 
 [DELETED] 
 [DELETED] 
 [DELETED] 
 [DELETED] 
 [DELETED] 
  
 (b)
Calculation: Assuming GAMBRO and Affiliates have fulfilled all requirements as described in Section 7(a) above, to qualify for the [DELETED], GAMBRO must achieve [DELETED] in the [DELETED], as that term is defined below, from the

  
 [DELETED], as that term is defined below, during each
[DELETED] Measurement Period, and such increase shall be defined as [DELETED]. 
  

					
	Amend No. 3 Agreement No. 200308359	 	- 11 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

 For purposes of this Section 7, [DELETED] shall mean the [DELETED] for each patient by GAMBRO
and its Affiliates AND the [DELETED] for each patient by GAMBRO and its Affiliates during the period [DELETED]; and [DELETED] shall mean the [DELETED] for each patient by GAMBRO and its Affiliates AND the [DELETED] for each patient by GAMBRO and its
Affiliates for each of the above referenced [DELETED] Measurement Periods. 
  
 Using the [DELETED] described above, the [DELETED] will be calculated as the percentage of patients within the [DELETED], by dividing the [DELETED] (for the purposes of this Agreement the [DELETED] shall be defined as
the number of patients who have at least one test within the reporting [DELETED] and the [DELETED] defined as follows: [DELETED], as shown below: 
  
 [DELETED] 
  
 Using the [DELETED] described above, which shall be calculated on a [DELETED] basis, the [DELETED] for each [DELETED] Measurement Period will be
calculated as the [DELETED], by [DELETED], as shown below: 
  
 [DELETED] 
  
 The [DELETED] shall then be calculated by
[DELETED], as shown below: 
  
 [DELETED] 
  
 The [DELETED] Rebate will be calculated on a [DELETED] basis in accordance
with Amgen’s discount calculation policies. Following determination of the [DELETED], Amgen shall then calculate GAMBRO’s [DELETED] Rebate in accordance with the following formula and the rebate tables listed below. 
  
 [DELETED] Rebate = A X B 
  
 Where 
  
 A = [DELETED] of EPOGEN® during the relevant [DELETED] Measurement Period. 
  
 B = A percent determined from [DELETED] in accordance with the schedule below. 
  
 C = [DELETED] 
  
 D = [DELETED] 
  
 [DELETED] Measurement Period 2 Rebate Table 
  

					
	 [DELETED]

	  	 [DELETED]

	  	 Rebate Percent
 (B)

	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]

  
 [DELETED]
Measurement Period 3 Rebate Table 
  

					
	 [DELETED]

	  	 [DELETED]

	  	 Rebate Percent
 (B)

	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]

  

					
	Amend No. 3 Agreement No. 200308359	 	- 12 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

 [DELETED] Measurement Period 4 Rebate Table 
  

					
	 [DELETED]

	  	 [DELETED]

	  	 Rebate Percent
 (B)

	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]

  
 [DELETED]
Measurement Period 5 Rebate Table 
  

					
	 [DELETED]

	  	 [DELETED]

	  	 Rebate Percent
 (B)

	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]

  
 [DELETED]
Measurement Period 6 Rebate Table 
  

					
	 [DELETED]

	  	 [DELETED]

	  	 Rebate Percent
 (B)

	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]
	[DELETED]	  	[DELETED]	  	[DELETED]

  

	*	Notwithstanding anything contained herein to the contrary, the maximum rebate percent payable for [DELETED] Measurement Period 2 shall not exceed [DELETED] and for [DELETED]
Measurement Periods 3, 4, 5, and 6 shall not exceed [DELETED] under this [DELETED] program. 

  
 (c) Payment: The [DELETED] will be calculated and paid to GAMBRO on a [DELETED] basis. Payment is contingent upon receipt by Amgen of all required
Data for the corresponding [DELETED] (including the [DELETED]). Such data must be submitted, on a [DELETED] basis, and no later than [DELETED] days after the end of each [DELETED]. If such data is received more than [DELETED] days after the last day
of any [DELETED] within a given [DELETED], the total Qualified Purchases of EPOGEN® attributable to GAMBRO during such [DELETED] will be excluded from the calculation of the [DELETED] for that [DELETED]. Notwithstanding the foregoing, if Amgen receives all required data from a minimum of
[DELETED] of all Affiliates within the time frame referenced above for any [DELETED] within a given [DELETED], the total Qualified Purchases of EPOGEN® attributable to GAMBRO and all Affiliates during such [DELETED], will be included in the calculation of the [DELETED] for that [DELETED].
However, if Amgen determines that any Affiliate is consistently not submitting the required data, Amgen and GAMBRO will work collaboratively in resolving such inconsistencies. Amgen reserves the right, in its sole discretion, to exclude any such
non-reporting Affiliate’s Qualified Purchases of EPOGEN® from the calculation of the [DELETED] for any relevant [DELETED]. 
  
 The [DELETED] discount will vest [DELETED] on the [DELETED] of [DELETED] respectively, and be paid [DELETED] in accordance with the terms and conditions
described above. 
  

					
	Amend No. 3 Agreement No. 200308359	 	- 13 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

	8.	[DELETED]. During the Term of this Agreement, GAMBRO may qualify for an [DELETED] as outlined below. 

  
 (a) Calculation: 
  
 [DELETED] 
  

	*	For the period [DELETED], GAMBRO may qualify to receive an [DELETED]. 

  
 (b) Payment and Vesting: The [DELETED] will vest at the end of each [DELETED] during the Term and will be paid on a [DELETED] basis in accordance
with Section 9 of this Agreement. 
  

	9.	Sponsorship. Through this agreement, Amgen and GAMBRO are working toward a common goal of improving patient outcomes. To achieve that goal, GAMBRO, throughout the Term of the
agreement, will be developing and providing education and training, along with tools, for its clinical staff, Medical Directors, admitting physicians, and at times, patients. It is understood that Amgen may provide to GAMBRO financial support and/or
materials and that Amgen is under no obligation to provide any sponsorships (“Sponsorship”) to assist GAMBRO in providing said education and training and tool development. To maintain compliance with applicable laws, rules, guidelines and
regulations, both GAMBRO and Amgen agree to implement the following process as it relates to possible sponsorship of education and training sessions and tool development. 

  
 GAMBRO agrees to provide to Amgen, within a reasonable period of time, a list of all proposed education and training
sessions, including Divisional meetings, scheduled for 2004. Such lists shall enable Amgen to plan for possible sponsorship for the upcoming year. Amgen understands that said lists shall only be proposed education and training sessions, and that
other sessions may be added, and some sessions may be deleted, by GAMBRO during the course of the respective calendar year. Such changes shall be communicated to Amgen within a reasonable time period. The lists shall include training
sessions/meeting topics, possible attendees and approximate date of meeting/training session. Additionally, it is understood by GAMBRO that Amgen may propose to GAMBRO potential sponsorship opportunities. 
  
 GAMBRO will [DELETED]. 
  
 Within a reasonable period of time, both GAMBRO and Amgen shall designate to
each other a contact(s) for their respective company to discuss potential sponsorship opportunities during the term of the agreement. The respective contact(s) shall ensure that all necessary documentation exists to support that the sponsorship
opportunity complies with applicable laws, rules, guidelines and regulations. All sponsorship opportunities must be communicated through each company’s respective contact(s). 
  
 Appendix B: List of GAMBRO Affiliates 
  
 (See attached Excel File 
 “Appendix B_AmendNo.3_200308359_11232004.xls”) 
  

					
	Amend No. 3 Agreement No. 200308359	 	- 14 -	 	 Ver. 11/24/04
 ACIS 10514

 Amendment No. 3 Agreement No. 200308359 (Continued) 
  

 Appendix C: List of GAMBRO Wholesalers 
  
 To ensure GAMBRO receives the appropriate discount, it is important Amgen receives
GAMBRO’S current list of Authorized Wholesalers. The following list represents the Wholesalers Amgen currently has associated with GAMBRO’S contract. Please update the list by adding or deleting Wholesalers as necessary. 
  
 American Medical Distributors, Inc. Subsidiary of Bellco Drug Corporation

 100 New Highway 
 Amityville,
NY 11701 
 CMA 600644 
  
 Bellco Drug Corporation 
 5500 New Horizons
Blvd 
 North Amityville, NY 11701 
 CMA 600051 
  

					
	Amend No. 3 Agreement No. 200308359	 	- 15 -	 	 Ver. 11/24/04
 ACIS 10514Corporate Integrity Agreement

 Exhibit 10.9 
  
 CORPORATE INTEGRITY AGREEMENT 
 BETWEEN THE 
 OFFICE OF INSPECTOR GENERAL 
 OF
THE 
 DEPARTMENT OF HEALTH AND HUMAN
SERVICES 
 AND 
 GAMBRO HEALTHCARE, INC. 
  

	I.	PREAMBLE 

  
 Gambro Healthcare, Inc. together with its indirect, direct, wholly-owned, and partially-owned subsidiaries and joint ventures in which Gambro
Healthcare, Inc. owns an interest of 5 percent or greater that provide outpatient dialysis services, including any holding companies owned by Gambro Healthcare, Inc., which in turn own the clinics providing outpatient dialysis services,
and their predecessors and successors, (collectively, Gambro) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote
compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements). Contemporaneously with this
CIA, Gambro is entering into Settlement Agreements with the United States in the Eastern District of Missouri, and the Eastern District of Pennsylvania, and this CIA is incorporated by reference into those Settlement Agreements. 
  
 Prior to the execution of this CIA, Gambro established a Corporate Compliance Program
(Compliance Program). This Compliance Program includes policies and procedures, an education and training component, mechanisms for ongoing monitoring and auditing of Gambro operations to assess compliance, mechanisms for employees and agents to
report incidents of noncompliance in an anonymous way, disciplinary actions for individuals violating compliance policies and procedures, and oversight of the compliance program by the Gambro Compliance Officer, Division Compliance Officers, and
Gambro’s Compliance Committee. Gambro agrees to continue to operate its Compliance Program for the term of this CIA. The Compliance Program may be modified as appropriate but, at a minimum, shall comply with the integrity obligations enumerated
in this CIA. 
  

	II.	TERM AND SCOPE OF THE CIA 

  
 A. The period of the compliance obligations assumed by Gambro under this CIA
shall be 5 years from the effective date of this CIA, unless otherwise specified. The effective date of this CIA shall be the effective date of the Settlement Agreement between the United States Attorney’s Office for the Eastern District of
Missouri and Gambro. (Effective Date). Each one-year period, beginning with the one-year period following the Effective Date, shall be referred to as a “Reporting Period.” 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 

 B. Sections VII, VIII, IX, X, and XI shall expire no later than 120 days after OIG’s receipt of:
(1) Gambro’s final annual report; or (2) any additional materials submitted by Gambro pursuant to OIG’s request, whichever is later. 
  
 C. The scope of this CIA shall be governed by the following definitions: 
  
 1. “Gambro Clinic” includes each outpatient dialysis clinic in which Gambro owns an interest of 5
percent or greater. 
  
 2. “Covered
Persons” includes: 
  
 a. all officers, directors, and
employees of Gambro; 
  
 b. all contractors, subcontractors,
agents, and other persons who provide patient care items or services or who perform billing or coding functions related to patient care on behalf of Gambro; 
  
 c. all Gambro Clinic medical directors (Medical Directors); and 
  

d. all physicians credentialed and privileged as active staff with Gambro who do not serve as Medical Directors (Covered Physicians). 
  
 Notwithstanding the above, with the exception of Medical Directors and Covered Physicians,
this term does not include part-time or per diem employees, contractors, subcontractors, agents, and other persons who are not reasonably expected to work more than 160 hours per year, except that any such individuals shall become “Covered
Persons” at the point when they work more than 160 hours during the calendar year. 
  
 3. “Relevant Covered Persons” shall include: 
  
 a. Negotiators: all Covered Persons who approve Arrangements, and shall include Regional Directors, Regional Vice
Presidents, Materials Management Personnel, Legal Personnel, Compliance Personnel, and Executives of Gambro; 
  
 b. Programmers: all Covered Persons involved in the design or programming of systems that impact diagnosis or procedure coding, reimbursement,
billing, or clinical documentation (collectively, Relevant Software); 
  
 c. Billers: all Covered Persons who input, code, or bill claims; 
  
 d. Medical Directors: the medical directors of all Gambro Clinics; 
  
 e. Clinic Compliance Liaisons: all Covered Persons designated by Gambro to act as liaison between a Gambro Clinic and the Compliance Officer, as
defined at Section III.A.3 below; and 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 2 

 f. Human Resources Staff: all Covered Persons involved directly in human resource functions that
include (1) excluded person background checks and/or (2) intake of Human Resource Employee Hotline telephone calls, and all Covered Persons who manage or supervise such Covered Persons. 
  
 4. “Arrangements” includes every arrangement or
transaction that (a) involves, directly or indirectly, the offer, payment, solicitation, or receipt of anything of value; and (b) is between Gambro and any actual or potential source of health care business or referrals to Gambro or any
actual or potential recipient of health care business or referrals from Gambro. The term “source” shall mean any physician, contractor, vendor, or agent, and the term “health care business or referrals” shall be read to include
referring, recommending, arranging for, ordering, leasing, or purchasing of any good, facility, item, or service for which payment may be made in whole or in part by Medicare, Medicaid, or any other Federal health care program (as defined in 42
U.S.C. § 1320a-7b(f)). The other party to an Arrangement shall be referred to herein as a “Contractor.” 
  

	III.	CORPORATE INTEGRITY OBLIGATIONS 

  
 Gambro shall maintain a Compliance Program that includes the following
elements: 
  
 A. Compliance Officer and Committee.

  
 1. Compliance Officer. Gambro
certifies that it has appointed an individual to serve as the Compliance Officer for Gambro. Gambro shall maintain a Compliance Officer for the term of the CIA. The Compliance Officer shall be responsible for developing and implementing policies,
procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with Federal health care program requirements. The Compliance Officer shall be a member of senior management of Gambro, shall make periodic (at
least quarterly) reports regarding compliance matters directly to the Board of Directors of Gambro, and shall be authorized to report on such matters to the Board of Directors at any time. The Compliance Officer shall not be, or be subordinate to,
the General Counsel or Chief Financial Officer. The Compliance Officer shall be responsible for monitoring the day-to-day compliance activities engaged in by Gambro as well as for any reporting obligations created under this CIA. 
  
 Gambro shall not assert a privilege to the OIG with respect to legal advice
or counsel Gambro obtains regarding Federal health care programs or Gambro’s compliance with the terms of this CIA from the Compliance Officer or any employee reporting to the Compliance Officer. The Compliance Officer or any employee reporting
to the Compliance Officer may seek legal advice without advance waiver of any applicable privilege from attorneys outside the Compliance Department. 
  
 Gambro shall report to OIG, in writing, any changes in the identity or position description of the Compliance Officer, or any actions or changes that
would affect the Compliance Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 3 

 2. Compliance Committee. Gambro certifies that it has a Compliance Committee in
place that includes the Gambro Compliance Officer and other members of senior management (senior executives supervising relevant departments, such as billing, clinical, human resources, audit, and operations) necessary to meet the requirements of
this CIA. The Compliance Officer shall chair the Compliance Committee and the Compliance Committee shall support the Compliance Officer in fulfilling his/her responsibilities (e.g., shall assist in the analysis of the organization’s risk
areas and shall oversee monitoring of internal and external audits and investigations). Gambro shall report to OIG, in writing, any changes in the composition of the Compliance Committee, or any actions or changes that would affect the Compliance
Committee’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change. 
  
 3. Clinic Compliance Liaison. Gambro shall designate the regional director for each Gambro Clinic to act as Clinic Compliance
Liaison (CCL). CCLs shall be responsible for overseeing compliance efforts at the clinic level. CCL duties shall include ensuring that clinic staff members complete applicable CIA and compliance related activities in a timely and effective manner
and working with the Compliance Officer to increase compliance awareness at the clinic level. The Compliance Officer shall maintain a list of all CCLs and the Gambro Clinics for which each CCL is responsible. This list shall be made available to OIG
upon request. 
  
 B. Written Standards. 
  
 1. Standards of Business Conduct. Gambro has
represented to OIG that it has a Standards of Business Conduct, and provided a copy of said document to OIG. Within 120 days after the Effective Date, Gambro shall revise, as necessary, and make available the written Standards of Business Conduct to
all Covered Persons, except Medical Directors and Covered Physicians. Gambro shall make the promotion of, and adherence to, the Standards of Business Conduct a requirement of continued employment and an element in evaluating the performance of all
employees where performance evaluations are conducted. The Standards of Business Conduct shall, at a minimum, set forth: 
  
 a. Gambro’s commitment to full compliance with all Federal health care program requirements, including its commitment to prepare and submit accurate
claims consistent with such requirements; 
  
 b. Gambro’s
requirement that all of its Covered Persons shall be expected to comply with all Federal health care program requirements and with Gambro’s own Policies and Procedures as implemented pursuant to this Section III.B (including the
requirements of this CIA); 
  
 c. the requirement that all of
Gambro’s Covered Persons shall be expected to report to the Compliance Officer or other appropriate individual designated by Gambro suspected violations of any Federal health care program requirements or of Gambro’s own Policies and
Procedures; 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 4 

 d. the possible consequences to both Gambro and Covered Persons of failure to comply with Federal health
care program requirements and with Gambro’s own Policies and Procedures and the failure to report such noncompliance; and 
  
 e. the right of all individuals to use the Disclosure Program described in Section III.F, and Gambro’s commitment to nonretaliation and to
maintain, as appropriate, confidentiality and anonymity with respect to such disclosures. 
  
 Within 120 days after the Effective Date, each Covered Person, except Medical Directors and Covered Physicians, shall certify, in writing or electronically, that he or she has been provided electronic access to, and
training on, and shall abide by Gambro’s Standards of Business Conduct. New Covered Persons, except Medical Directors and Covered Physicians, shall receive the training and access to the Standards of Business Conduct and shall complete the
required certification within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. 
  
 Within 60 days of the Effective Date, Gambro shall provide each Medical Director and Covered Physician a copy of the Compliance Critical Concepts as well
as electronic access to Gambro’s Standards of Business Conduct. This document will cover the topics discussed in Section III.B.1. New Medical Directors and Covered Physicians shall receive a copy of the Compliance Critical Concepts and
electronic access to Gambro’s Standards of Business Conduct within 30 days after becoming a Medical Director or Covered Physician or within 60 days after the Effective Date, whichever is later. In addition, Gambro shall obtain certification
from Medical Directors and Covered Physicians through training and in accordance with the requirements specified in Sections III.C.3 and III.C.4. 
  
 Gambro shall periodically review the Standards of Business Conduct to determine if revisions are appropriate and shall make any necessary revisions based
on such review. Any revised Standards of Business Conduct shall be distributed within 30 days after any revisions are finalized. 
  
 2. Policies and Procedures. Within 120 days after the Effective Date, Gambro shall review, and where appropriate revise, its
written Policies and Procedures regarding the operation of Gambro’s compliance program and its compliance with Federal health care program requirements. At a minimum, the Policies and Procedures shall address: 
  
 a. the subjects relating to the Standards of Business Conduct identified in
Section III.B.1; 
  
 b. the applicability of Federal health
care program requirements to Gambro’s various business activities, including the negotiation of Arrangements, the designing and programming of Relevant Software, and the billing and coding of claims; 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 5 

 c. 42 U.S.C. § 1320a-7b(b) (the “Anti-Kickback Statute”), and the regulations and other
guidance documents related to the Anti-Kickback Statute, and business or financial arrangements or contracts that induce the unlawful referral of Federal health care program beneficiaries in violation of the Anti-Kickback Statute; 
  
 d. the requirements set forth in Sections III.D and E; and 
  
 e. the billing of Stat Lab tests, as defined in Appendix E, in a
manner that will protect the Federal health care program from overpayments. 
  
 Within 120 days after the Effective Date, the relevant portions of the Policies and Procedures shall be made available to all individuals whose job functions relate to those Policies and Procedures. Appropriate and
knowledgeable staff shall be available to explain the Policies and Procedures. 
  
 At least annually (and more frequently, if appropriate), Gambro shall assess and update as necessary the Policies and Procedures. Within 30 days after the effective date of any revisions, the relevant portions of any
such revised Policies and Procedures shall be made available to all individuals whose job functions relate to those Policies and Procedures. 
  
 C. Training and Education. 
  
 1. General Training. Within 120 days after the Effective Date, Gambro shall provide at least two hours of General Training to each
Covered Person, excluding Medical Directors and Covered Physicians. This training, at a minimum, shall explain: 
  
 a. Gambro’s CIA requirements; and 
  
 b. Gambro’s Compliance Program (including the Standards of Business Conduct and the Policies and Procedures as they pertain to general compliance
issues). 
  
 New Covered Persons shall receive the General Training described
above within 30 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. After receiving the initial General Training described above, each Covered Person shall receive at least one hour of General
Training annually in subsequent Reporting Periods. 
  
 If,
pursuant to Gambro’s Compliance Program, Gambro has provided General Training to Covered Persons that satisfies the requirements set forth above in Section III.C.1 within one (1) month prior to the Effective Date, the OIG shall credit
the training for purposes of satisfying Gambro’s General Training obligations for the first Reporting Period of this CIA. 
  
 2. Specific Training. Within 150 days after the Effective Date, the following Specific Training shall be provided to the applicable
Relevant Covered Persons. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 6 

 a. Negotiation Training: Each Negotiator shall receive at least two hours of Negotiation
Training in addition to the General Training required above. This Negotiation Training shall include a discussion of: 
  
 i. the legal sanctions and consequences for improper contracting or financial arrangements; 
  
 ii. examples of violations of the Anti-Kickback Statute; 
  
 iii. a review of Gambro’s contracting Policies and Procedures related
to Arrangements, as defined in Section II.C.3 above and as developed pursuant to Sections III.B.2 and III.D, and the personal obligation of each individual involved in the development or maintenance of Arrangements to know applicable legal
requirements and Gambro’s Policies and Procedures; and 
  
 iv. the specific applicability of the Anti-Kickback Statute, Federal health care program requirements, and Gambro policies and procedures to the negotiation and maintenance of all types of Arrangements entered into by Gambro, including
joint ventures with physicians and Federal health care providers, Medical Director contracts, and physician credentialing. 
  
 b. Billing Training: Each Biller shall receive at least two hours of Billing Training, which shall include a discussion of: 
  
 i. the Federal health care program requirements regarding the accurate
coding and submission of claims; 
  
 ii. policies, procedures,
and other requirements applicable to the documentation of medical records; 
  
 iii. the personal obligation of each individual involved in the claims submission process to ensure that such claims are accurate; 
  
 iv. applicable reimbursement statutes, regulations, and program requirements and directives; 
  
 v. the legal sanctions for violations of the Federal health care program
requirements; and 
  
 vi. examples of proper and improper claims
submission practices. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 7 

 c. Programming Training: Each Programmer shall receive at least one hour of Programming
Training, which shall include a discussion of: 
  
 i. the
obligation of each Programmer to comply with all Federal health care program rules and regulations; 
  
 ii. the Federal health care program requirements regarding the accurate coding and submission of claims; 
  
 iii. Federal health care program requirements, internal Policies and
Procedures, and other requirements applicable to the documentation of medical records; 
  
 iv. the process by which Gambro codes claims for reimbursement by Medicare and Medicaid; 
  
 v. the effect of programming and design choices on the submission of claims to Medicare and Medicaid; 
  
 vi. the legal, regulatory, and internal Gambro sanctions for improper
conduct; and 
  
 vii. examples of proper and improper conduct.

  
 The Programming Training shall be designed to assist each
Programmer in recognizing the potential effects of Programming decisions on Gambro’s compliance with Federal health care program requirements, e.g. how a Relevant Software program or program element might cause Gambro to engage in
noncompliant acts or result in the submission of a false or inaccurate claim to Medicare or Medicaid. 
  
 d. CCL Training: Each CCL shall receive one hour of CCL Training, which shall include a discussion of: 
  
 i. the purpose of the CIA; 
  
 ii. the obligations of Clinic staff members under the CIA; 
  
 iii. the role of the Compliance Officer and compliance staff; 

 
 iv. the role and availability of Gambro’s Disclosure Program; and

  
 v. methods of explaining the importance of, and encouraging
the practice of, compliance and CIA requirements to Clinic staff. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 8 

 e. Human Resources Personnel Training. Each Human Resources Staff member shall receive one
hour of training, which shall include a discussion of the following: 
  
 i. statutes and regulations pertaining to the exclusion of individuals and companies from the Federal health care programs; 
  
 ii. the legal consequences to Gambro of employing or contracting with excluded individuals or companies; 
  
 iii. Gambro’s Disclosure Program, with specific reference to the
purpose and operation of the Employee Hotline; 
  
 iv. the role
and duties of the Compliance Officer; and 
  
 v. the
identification and referral of compliance complaints or matters to the Compliance Officer. 
  
 Relevant Covered Persons shall receive the applicable Specific Training within 60 days after the beginning of their employment or becoming Relevant Covered Persons, or within 120 days after the Effective Date,
whichever is later. A Gambro employee who has completed the applicable Specific Training shall supervise a new Relevant Covered Person’s work, to the extent that the work relates to the topics covered by the applicable Specific Training, until
such time as the new Relevant Covered Person completes his or her applicable Specific Training. 
  
 If, pursuant to Gambro’s Compliance Program, Gambro has provided Specific Training to Covered Persons that satisfies the requirements set forth above
in Section III.C.2 within four (4) months prior to the Effective Date, the OIG shall credit the training for purposes of satisfying Gambro’s Specific Training obligations for the first Reporting Period of this CIA. 
  
 After receiving the initial applicable Specific Training described in this
Section, each Relevant Covered Person shall receive, as applicable, at least two hours of Negotiation Training, one hour of Billing Training, one hour of Programming Training, one hour of CCL Training, and/or one hour of Human Resources Staff
Training annually in subsequent Reporting Periods. 
  
 3. Medical Director Training: Within seven months after the Effective Date, Gambro shall develop and implement a special Medical Director training and education program (Medical Director Training). Medical Directors shall only be
required to receive the Medical Director Training delineated in this Section III.C.3, which shall include two hours of Initial Medical Director Training covering: 
  
 a. the purpose of the CIA; 
  
 b. Gambro’s compliance program (including the Standards of Business Conduct and the Policies and Procedures as they pertain to Medical Directors);

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 9 

 c. medical necessity and coverage requirements of the Federal health care programs; 
  
 d. documentation requirements of the Federal health care programs;

  
 e. the requirements of the Anti-Kickback Statute;

  
 f. the legal consequences to Gambro and Medical Directors of
Anti- Kickback Statute violations; and 
  
 g. other Federal
health care program requirements and Gambro policies and procedures directly related to the duties and responsibilities of Medical Directors. 
  
 After receiving the Initial Medical Directors Training, each Medical Director shall receive at least two hours of Supplemental Medical Director Training
annually in subsequent Reporting Periods, which shall review the topics covered in the Initial Medical Director Training and include material changes in Federal health care program requirements, changes in Gambro policies and procedures, and changes
in the Gambro corporate compliance program. 
  
 All new contracts
or contract amendments between Gambro and its Medical Directors executed after the Effective Date of this CIA shall include a specific obligation on the part of the Medical Director to receive at least two hours of Initial Medical Director Training
within seven months after the Effective Date or within 60 days after beginning to provide medical director services under the first new contract or contract amendment executed on or after the Effective Date, whichever is later; and thereafter the
annual Supplemental Medical Director Training. For all other contracts between Gambro and its Medical Directors that are in force on the Effective Date, Gambro shall provide the Initial Medical Director Training and annual Supplemental Medical
Director Training to the Medical Directors as set forth in this Paragraph and use its best efforts to encourage attendance and participation by the Medical Directors. 
  
 Each Medical Director who attends Medical Director Training shall certify, in writing, (or in electronic form, if they have
received computer-based training) that he or she has received the training. The certification shall specify the type of training received and the date received. The Compliance Officer shall retain the certifications, along with all course materials.
The certifications shall be made available to OIG, upon request. 
  
 The Compliance Officer shall also maintain records of the number of Medical Directors and the percentage of Medical Directors who attend Medical Director Training, and shall provide such records to OIG as part of its Implementation and
Annual Reports. 
  
 4. Covered Physician
Training. Within six months of the Effective Date, Gambro shall develop and implement a special Covered Physician training and education program (Covered Physician Training). Covered Physicians shall only be required to receive the Covered
Physician Training delineated in this Section III.C.4, which shall include two hours of Initial Covered Physician Training covering: 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 10 

 a. the purpose of the CIA; 
  
 b. Gambro’s compliance program (including the Standards of Business Conduct and the Policies and Procedures as they
pertain to Covered Physicians); 
  
 c. medical necessity and
coverage requirements of the Federal health care programs; 
  
 d. documentation requirements of the Federal health care programs; 
  
 e. the requirements of the Anti-Kickback Statute; 
  
 f. the legal consequences to Gambro and Covered Physicians of Anti-Kickback Statute violations; and 
  
 g. other Federal health care program requirements and Gambro policies and procedures directly related to the duties and responsibilities of Covered
Physicians. 
  
 After receiving the Initial Covered Physician
Training, each Covered Physician shall receive at least two hours of Supplemental Covered Physician Training in subsequent Reporting Periods, which shall review the topics covered in the Initial Covered Physician Training and include material
changes in Federal health care program requirements, changes in Gambro policies and procedures, and changes in the Gambro corporate compliance program. 
  
 Gambro shall make Covered Physician Training available to all Covered Physicians, and shall use its best efforts to encourage their attendance and
participation at such training. Each Covered Physician who attends Covered Physician Training shall certify, in writing, (or in electronic form, if they have received computer-based training) that he or she has received the training. The
certification shall specify the type of training received and the date received. The Compliance Officer shall retain the certifications, along with all course materials. The certifications shall be made available to OIG, upon request. 
  
 The Compliance Officer shall also maintain records of the number of Covered
Physicians and the percentage of Covered Physicians who attend Covered Physician Training, and shall provide such records to OIG as part of its Implementation and Annual Reports. 
  
 5. Certification. Each individual who is required to attend training shall certify, in writing, or in
electronic form, if applicable, that he or she has received the required training. The certification shall specify the type of training received and the date received. The Compliance Officer (or designee) shall retain the certifications, along with
all course materials. These shall be made available to OIG upon request. 
  
 6. Qualifications of Trainer. Persons providing the training (Trainers) shall be knowledgeable about the subject area. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 11 

 7. Update of Training. Gambro shall annually review the training, and, where
appropriate, update the training to reflect changes in Federal health care program requirements, any issues discovered during internal audits or the IRO Claims Review, Unallowable Cost Review, Stat Lab Systems Review, Arrangements Review, or
Heightened Arrangements Review, and any other relevant information. 
  
 8. Computer-based Training. Gambro may provide the training required under this CIA through appropriate computer-based training approaches. If Gambro chooses to provide computer-based training, it shall make
available appropriately qualified and knowledgeable staff or Trainers to answer questions or provide additional information to the individuals receiving such training. 
  
 9. Self-Guided Study. All training, except for Computer-based Training, shall be conducted as a class
by a Trainer, unless otherwise agreed upon in writing by OIG. 
  
 D. Contractual Compliance With the Anti-Kickback Statute. 
  
 This Section applies to all Arrangements, as defined at section II.C.3. As used in this Section, Arrangements shall also refer to all written versions of Arrangements. The party(ies) to an Arrangement other than
Gambro shall be referred to herein as a “Contractor.” 
  
 1. Arrangements Procedures. Within 120 days after the Effective Date, Gambro shall create procedures reasonably designed to ensure that each Arrangement does not violate the Anti-Kickback Statute. Within 210
days after the Effective Date, Gambro shall implement the procedures. As part of these procedures Gambro shall ensure that the following requirements are implemented for each Arrangement: 
  
 a. the Arrangement shall be set forth in writing and signed by Gambro and
the Contractor(s); 
  
 b. Gambro shall make available to all
individuals who meet the definition of Covered Persons the applicable training, as set forth in Section III.C; and 
  
 c. Gambro shall provide each Contractor with a copy of its Critical Compliance Concepts and Anti-Kickback Policies and Procedures. 
  
 Gambro shall create an appropriate corrective action plan for any existing
Arrangement that does not meet the requirements set forth above or that violate the Anti-Kickback Statute. 
  
 2. Relevant Arrangements Review. Within 210 days after the Effective Date, Gambro shall create a database following the
instructions set forth in Appendix A pertaining to all Relevant Arrangements, as defined in Appendix A. This database shall be available for OIG review upon request. Gambro shall create an appropriate corrective action plan for any
Relevant Arrangement that does not meet the requirements set forth at Section III.D.1 or that violates the Anti-Kickback Statute. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 12 

 3. New Arrangements and Renewed Existing Arrangements. Prior to entering into any
new Arrangements or renewing any existing Arrangements, Gambro shall ensure that the Arrangements do not violate the Anti-Kickback Statute. In addition to the requirements set forth in Section III.D.l, Gambro shall also ensure that all new
Arrangements and renewed existing Arrangements comply with the following requirements: 
  
 a. the Arrangement shall include a provision that all individuals who meet the definition of Covered Persons shall comply with Gambro’s Compliance Program, including the training related to the Anti-Kickback
Statute; 
  
 b. Gambro shall certify and shall require
Contractor(s) to certify, at the time of signing the Arrangement, and upon contract renewal, that the Arrangement is not intended to generate referrals for services or supplies for which payment may be made in whole or in part under any Federal
health care program; and 
  
 c. Gambro shall require the
Contractor(s) to certify, at the time of signing the Arrangement, that the Contractor(s) shall comply with Gambro’s compliance program and with the Anti-Kickback Statute in all matters involving Gambro. 
  
 4. Heightened Review of Arrangements. During each of
the five Reporting Periods, Gambro shall perform Heightened Arrangements Review on its existing Relevant Arrangements. The Heightened Arrangements Review shall consist of three separate samples (Arrangement Samples). The Arrangement Samples shall be
selected according to the procedure set forth in Appendix B. The Heightened Arrangements Review shall consist of an investigation on the initiation, negotiation, maintenance, performance, and, if relevant, dissolution of each Relevant
Arrangement in the Arrangement Samples. The Heightened Arrangements Review shall be conducted according to the instructions set forth in Appendix B. 
  
 5. Heightened Arrangements Review Report. Gambro shall prepare a summary of its findings from the Heightened Arrangements Review
(Heightened Arrangements Review Report). The Heightened Arrangements Review Report shall be included in Gambro’s Annual Report to the OIG. 
  
 6. Documents Related to Arrangements. 
  
 a. Gambro shall retain for a period of six years, and make available to OIG upon request: (1) copies of all Arrangements subject to
Section III.D; and (2) all non-privileged documents and communications relating to the Arrangements and the actual performance of duties under the Arrangements. 
  
 b. Nothing in this CIA, or any other communication or report made pursuant to the CIA, shall constitute a waiver by Gambro
of its attorney-client, attorney-work product, or other applicable privileges. 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 13 

 
Notwithstanding that fact, the existence of any such privilege shall not be used by Gambro to avoid its obligations to comply with the provisions of this
CIA. 
  
 c. With respect to the documents reviewed, created,
used, or relied upon in connection with the Heightened Arrangements Review, Gambro shall not assert any rights or privileges that may otherwise apply to the production of such documents to the OIG. 
  
 E. Review Procedures. 
  
 1. Independent Review Organization 
  
 a. Engagement of Independent Review Organization. 

 
 i. Within 120 days after the Effective Date, Gambro shall engage an
entity (or entities), such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform reviews to assist Gambro in assessing and evaluating its billing and coding practices
pursuant to the obligations of this Agreement and the Settlement Agreement. The applicable requirements relating to the IRO are outlined in Appendix C to this Agreement, which is incorporated by reference. 
  
 Each IRO engaged by Gambro shall have expertise in the billing, coding,
reporting, and other requirements of the Federal health care programs’ end-stage renal disease benefit and in the general requirements of the Federal health care program(s) from which Gambro seeks reimbursement. Each IRO shall assess, along
with Gambro, whether it can perform the IRO review in a professionally independent and/or objective fashion, as appropriate to the nature of the engagement, taking into account any other business relationships or other engagements that may exist.

  
 ii. In the second or any subsequent Reporting Period Gambro
may submit to OIG a request to conduct internal reviews of the billing review required by Sections III.E.2 and III.E.3 (the “Billing Review”). At the sole discretion of OIG, Gambro may perform the Billing Review for the first six months of
the Reporting Period, which Billing Review shall comply with all of the requirements outlined in Sections III.E.2 and III.E.3. Gambro shall submit such Billing Review to OIG within eight (8) months after the beginning of the Reporting Period.
The Billing Review performed by Gambro shall also include a report from an IRO that verifies that the Billing Review requirements have been satisfied. As part of any such verification performed by an IRO under this CIA, the IRO shall conduct a
review of at least 20% of the claims reviewed by 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 14 

 
Gambro in performing its internal review. If, in its sole discretion, OIG determines that such internal review satisfactorily establishes the adequacy of
Gambro’s billing practices pursuant to this CIA, OIG may allow Gambro to perform the Billing Review (with verification from the IRO) covering the second six months of the second Reporting Period in conformance with Section III.E.2 and
III.E.3 in lieu of the IRO conducting the Billing Review for the entire second Reporting Period. Similarly, OIG may, in its sole discretion, allow Gambro to continue to perform the Billing Review (with verification by the IRO) in conformance with
Sections III.E.2 and III.E.3 for the remaining Reporting Periods of this CIA in lieu of the IRO conducting the Billing Review for those Reporting Periods. To the extent that OIG permits Gambro to perform the Billing Review, then Gambro must submit
all the information required in the sections of this CIA governing the Billing Review performed (Sections III.E.2 and/or III.E.3), as well as the results of the IRO’s verification. 
  
 b. General Review Procedures. 
  
 i. Reviews. The IRO(s) review shall evaluate and analyze: 
  
 A. Gambro’s coding, billing, and claims submission to the Federal
health care programs and the reimbursement received (Claims Review); 
  
 B. whether Gambro sought payment for certain unallowable costs (Unallowable Cost Review); and 
  
 C. Gambro’s requests for Stat Lab services and whether any double billing has occurred for laboratory tests performed as Stat Lab tests (Stat Lab
Systems Review). 
  
 ii. Frequency of Claims and Stat Lab
Systems Review. The Claims Review and the Stat Lab Systems Review shall be performed annually and shall cover each of the Reporting Periods. The IRO(s) shall perform all components of each annual Claims Review and Stat Lab Systems Review,
except by prior agreement with OIG under the provisions set forth elsewhere in this CIA. 
  
 iii. Frequency of Unallowable Cost Review. If applicable, the IRO shall perform the Unallowable Cost Review for the first Reporting Period. 
  
 c. Retention of Records. The IRO and Gambro shall retain and make available to OIG, upon request, all work papers,
supporting 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 15 

 
documentation, correspondence, and draft reports (those exchanged between the IRO and Gambro) related to the reviews. 
  
 2. Claims Review. The Claims Review shall include a
Discovery Sample and, if necessary, a Full Sample. The applicable definitions, procedures, and reporting requirements are outlined in Appendix D to this Agreement, which is incorporated by reference. 
  
 a. Discovery Sample. The IRO shall randomly select and review a
sample of 10 Beneficiary Paid Claims from each of the Clinics in the Sampling Frame. 
  
 All the Paid Claims shall be reviewed based on the supporting documentation available at Gambro’s office or under Gambro’s control and applicable billing and coding regulations and guidance to determine
whether the claim was correctly coded, submitted, and reimbursed. 
  
 i. If the Error Rate (as defined in Appendix D) for the Discovery Sample is less than 5%, no additional sampling is required, nor is the Systems Review required. (Note: The guidelines listed above do not imply that this is an
acceptable error rate. Accordingly, Gambro should, as appropriate, further analyze any errors identified in the Discovery Sample. Gambro recognizes that OIG or other HHS component, in its discretion and as authorized by statute, regulation, or other
appropriate authority may also analyze or review Paid Claims included, or errors identified, in the Discovery Sample or any other segment of the universe.) 
  
 ii. If the Discovery Sample indicates that the Error Rate is 5% or greater, the IRO shall perform a Full Sample and a Systems Review, as described below.

  
 b. Full Sample. If necessary, as determined by
procedures set forth in Section III.E.2.a, the IRO shall perform an additional sample of Beneficiary Paid Claims using commonly accepted sampling methods and in accordance with Appendix D. The Full Sample shall be designed to:
(i) estimate the actual Overpayment in the population with a 90% confidence level and with a maximum relative precision of 25% of the point estimate; and (ii) conform with the Centers for Medicare and Medicaid Services’ statistical
sampling for overpayment estimation guidelines. The Paid Claims shall be reviewed based on supporting documentation available at Gambro’s office or under Gambro’s control and applicable billing and coding regulations and guidance to
determine whether the claim was correctly coded, submitted, and reimbursed. For purposes of calculating the size of the Full Sample, the Discovery Sample may serve as the probe sample, if statistically appropriate. Additionally, Gambro may use the
Beneficiary Paid Claims sampled as part of the 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 16 

 
Discovery Sample, and the corresponding findings for those 10 Beneficiary Paid Claims from each of the Clinics in the Sampling Frame, as part of its Full
Sample, if: (i) statistically appropriate and (ii) Gambro selects the Full Sample Items using the seed number generated by the Discovery Sample. OIG, in its sole discretion, may refer the findings of the Full Sample (and any related
workpapers) received from Gambro to the appropriate Federal health care program payor, including the Medicare contractor (e.g., fiscal intermediary), for appropriate follow-up by that payor. 
  
 c. Systems Review. If Gambro’s Discovery Sample identifies an
Error Rate of 5% or greater, Gambro’s IRO shall also conduct a Systems Review. Specifically, for each claim in the Discovery Sample and Full Sample that resulted in an Overpayment, the IRO shall perform a “walk through” of the
system(s) and process(es), that generated the claim to identify any problems or weaknesses that may have resulted in the identified Overpayments. The IRO shall provide its observations and recommendations on suggested improvements to the system(s)
and the process(es) that generated the claim. 
  
 d.
Repayment of Identified Overpayments. In accordance with Section III.I.1 of this Agreement, Gambro shall repay within 30 days any Overpayment(s) identified in the Discovery Sample or the Full Sample (if applicable), regardless of the
Error Rate, to the appropriate payor and in accordance with payor refund policies. Gambro shall make available to OIG any and all documentation and the associated documentation that reflects the refund of the Overpayment(s) to the payor. 

 
 3. Claims Review Report. The IRO shall prepare a
report based upon the Claims Review performed (Claims Review Report). Information to be included in the Claims Review Report is described in Appendix D. 
  

4. Unallowable Cost Review. If applicable, the IRO shall conduct a review of Gambro’s compliance with the unallowable cost
provisions of the Settlement Agreement. The IRO shall determine whether Gambro has complied with its obligations not to charge to, or otherwise seek payment from, federal or state payors for unallowable costs (as defined in the Settlement Agreement)
and its obligation to identify to applicable federal or state payors any unallowable costs included in payments previously sought from the United States, or any state Medicaid program. This unallowable cost analysis shall include, but not be limited
to, payments sought in any cost reports, cost statements, information reports, or payment requests already submitted by Gambro or any affiliates. To the extent that such cost reports, cost statements, information reports, or payment requests, even
if already settled, have been adjusted to account for the effect of the inclusion of the unallowable costs, the IRO shall determine if such adjustments were proper. In making this determination, the IRO may need to review cost reports and/or
financial statements from the year in which the Settlement Agreement was executed, as well as from previous years. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 17 

 5. Unallowable Cost Review Report. If applicable, the IRO shall prepare a report
based upon the Unallowable Cost Review performed. The Unallowable Cost Review Report shall include the IRO’s findings and supporting rationale regarding the Unallowable Costs Review and whether Gambro has complied with its obligation not to
charge to, or otherwise seek payment from, federal or state payors for unallowable costs (as defined in the Settlement Agreement) and its obligation to identify to applicable federal or state payors any unallowable costs included in payments
previously sought from such payor. 
  
 6. Stat
Lab Systems Review. The Stat Lab Systems Review shall consist of a review of Stat Lab requisitions, invoices and associated Stat Lab agreements, where available. The purpose of this review is to identify Overpayments for Stat Lab tests through
an examination of systems and processes connected to the billing of Stat Lab tests to Federal health care programs. The applicable definitions, procedures, and reporting requirements are outlined in Appendix E to this Agreement, which is
incorporated by reference. 
  
 a. Sample Selection. The
IRO shall randomly select and review a sample of 50 Stat Lab Requisitions from the Sampling Frame. 
  
 b. Review Process. All Stat Lab Requisitions shall be reviewed based on the supporting documentation available at Gambro’s office or under
Gambro’s control. 
  
 i. Each Stat Lab requisition shall be
reviewed for instructions for billing, test results, indication of billing by the Stat Lab to Gambro, and Stat Lab agreements, where available (collectively, Stat Lab Files). For each Stat Lab test where there is no indication that the laboratory
billed Gambro for the Stat Lab test, the IRO shall determine whether an Overpayment occurred through reimbursement under the composite rate. Upon determination of that an Overpayment exists, Gambro shall repay within 30 days any amounts due to the
appropriate payor and in accordance with payor refund policies as required Section III.1.1. Gambro shall make available to OIG any and all documentation and the associated documentation that reflects the repayment of the Overpayment(s) to the
payor. 
  
 ii. If there are Overpayments, incomplete Stat Lab
Files, or no indication of appropriate billing by the Stat Lab, Gambro should further analyze and determine the root cause of any deficiencies identified in the Sample. In conjunction with the IRO, Gambro will develop improvements to the system(s)
and process(es) that created the deficiency. 
  
 During subsequent
Reporting Periods, Gambro shall submit a workplan for OIG approval setting forth a modified systems review for Stat Lab Systems Review. In the third or any subsequent Reporting Period, Gambro may request that the Stat Lab Systems Review be 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 18 

 
discontinued. The decision to discontinue the Stat Lab Systems Review shall be at the sole discretion of OIG. 
  
 7. Stat Lab Systems Review Report. The IRO shall
prepare a report based upon the Stat Lab Systems Review performed (Stat Lab Systems Review Report). Information to be included in the Stat Lab Systems Review Report is described in Appendix E. 
  
 8. Validation Review. In the event OIG has reason to
believe that: (a) Gambro’s Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review fails to conform to the requirements of this Agreement; or (b) Gambro’s or the IRO’s findings or
Heightened Arrangements Reviewed results, Claims Review results, Unallowable Cost Review results, or Stat Lab Systems Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Heightened
Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review complied with the requirements of the Agreement and/or the findings or Heightened Arrangements Review results, Claims Review results, Unallowable Cost Review
results, or Stat Lab Systems Review results are inaccurate (Validation Review). Gambro shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of
Gambro’s final Annual Report shall be initiated no later than one year after Gambro’s final submission (as described in Section II) is received by OIG. 
  
 Prior to initiating a Validation Review, OIG shall notify Gambro of its intent to do so and provide a written explanation of
why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Gambro may request a meeting with OIG to: (a) discuss the results of any Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab
Systems Review submissions or findings; (b) present any additional information to clarify the results of the Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review or to correct the inaccuracy of the
Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review; and/or (c) propose alternatives to the proposed Validation Review. Gambro agrees to provide any additional information as may be requested by
OIG under this Section in an expedited manner. OIG will attempt in good faith to resolve any Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review issues with Gambro prior to conducting a Validation
Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG. 
  
 9. Independence/Objectivity Certification. The IRO(s) shall include in its report(s) to Gambro a certification or sworn affidavit
that it has evaluated its professional independence and/or objectivity, as appropriate to the nature of the engagement, with regard to the Claims Review, Unallowable Cost Review, or Stat Lab Systems Review and that it has concluded that it is, in
fact, independent and/or objective. 
  
 F. Disclosure
Program. 
  
 Gambro shall maintain a Disclosure Program that
includes a mechanism (e.g., a toll-free compliance telephone line) to enable individuals to disclose, to the Compliance Officer or some 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 19 

 
other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Gambro’s policies,
conduct, practices, or procedures with respect to a Federal health care program believed by the individual to be a potential violation of criminal, civil, or administrative law. Gambro shall appropriately publicize the existence of the disclosure
mechanism (e.g., via periodic emails to employees or by posting the information in prominent common areas). 
  
 The Disclosure Program shall emphasize a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for
which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Compliance Officer (or designee) shall make a
preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is
sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Gambro shall conduct an internal review of the
allegations set forth in the disclosure and ensure that proper follow-up is conducted. 
  
 The Compliance Officer (or designee) shall maintain a disclosure log, which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and
any corrective action taken in response to the internal reviews. The disclosure log shall be made available to OIG, upon request. 
  
 G. Ineligible Persons. 
  
 1. Definitions. For purposes of this CIA: 
  

a. an “Ineligible Person” shall include an individual or entity who: 
  
 i. is currently excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs
or in Federal procurement or nonprocurement programs; or 
  
 ii.
has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. 
  
 b. “Exclusion Lists” include: 
  
 i. the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov); and

  
 ii. the General Services Administration’s List of
Parties Excluded from Federal Programs (available through the Internet at http://epls.arnet.gov). 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 20 

 c. “Screened Persons” include prospective and current owners (other than shareholders who:
(1) have an ownership interest of less than 5%; and (2) acquired the ownership interest through public trading), officers, directors, employees, contractors, and agents of Gambro. 
  
 2. Screening Requirements. Gambro shall ensure that
all Screened Persons are not Ineligible Persons, by implementing the following screening requirements: 
  
 a. Gambro shall screen all Screened Persons against the Exclusion Lists prior to engaging their services and, as part of the hiring or contracting
process, shall require such persons to disclose whether they are an Ineligible Person. 
  
 b. Gambro shall screen all Screened Persons against the Exclusion Lists within 120 days after the Effective Date and on an annual basis thereafter. 
  
 c. Gambro shall implement a policy requiring all Screened Persons to disclose immediately any debarment, exclusion,
suspension, or other event that makes that person an Ineligible Person. 
  
 Nothing in this Section affects the responsibility of (or liability for) Gambro to refrain from billing Federal health care programs for items or services furnished, ordered, or prescribed by an Ineligible Person. 
  
 3. Removal Requirement. If Gambro has actual notice
that a Screened Person has become an Ineligible Person, Gambro shall remove such person from responsibility for, or involvement with, Gambro’s business operations related to the Federal health care programs and shall remove such person from any
position for which the person’s compensation or the items or services furnished, ordered, or prescribed by the person are paid in whole or part, directly or indirectly, by Federal health care programs or otherwise with Federal finds at least
until such time as the person is reinstated into participation in the Federal health care programs. 
  
 4. Pending Charges and Proposed Exclusions. If Gambro has actual notice that a Screened Person is charged with a criminal offense
that falls within the ambit of 42 U.S.C. §§ l320a-7(a), 1320a-7(b)(l)-(3), or is proposed for exclusion during his or her employment or contract term or, in the case of a Covered Physician, during the term of the Covered Physician’s
clinic privileges, Gambro shall take all appropriate actions to ensure that the responsibilities of that person have not and shall not adversely affect the quality of care rendered to any beneficiary, patient, or resident, or the accuracy of any
claims submitted to any Federal health care program. 
  
 H.
Notification of Government Investigation or Legal Proceedings. 
  
 Within 30 days after discovery, Gambro shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to Gambro conducted or brought by a governmental entity or its agents involving an allegation that Gambro has
committed a crime or has engaged in 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 21 

 
fraudulent activities. This notification shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the
status of such investigation or legal proceeding. Gambro shall also provide written notice to OIG within 30 days after the resolution of the matter, and shall provide OIG with a description of the findings and/or results of the investigation or
proceedings, if any. 
  
 I. Reporting. 
  
 1. Overpayments. 
  
 a. Definition of Overpayments. For purposes of this CIA, an
“Overpayment” shall mean the amount of money Gambro has received in excess of the amount due and payable under any Federal health care program requirements. 
  
 b. Reporting of Overpayments. If, at any time, Gambro identifies or learns of any Overpayment, Gambro shall
notify the payor (e.g., Medicare fiscal intermediary) within 30 days after identification of the Overpayment and take remedial steps within 60 days after identification (or such additional time as may be agreed to by the payor) to correct the
problem, including preventing the underlying problem and the Overpayment from recurring. Also, within 30 days after identification of the Overpayment, Gambro shall repay the Overpayment to the appropriate payor to the extent such Overpayment has
been quantified. If not yet quantified, within 30 days after identification, Gambro shall notify the payor of its efforts to quantify the Overpayment amount along with a schedule of when such work is expected to be completed. Notification and
repayment to the payor shall be done in accordance with the payor’s policies, and, for Medicare contractors, shall include the information contained on the Overpayment Refund Form, provided as Appendix F to this CIA. Notwithstanding the
above, notification and repayment of any Overpayment amount that routinely is reconciled or adjusted pursuant to policies and procedures established by the payor should be handled in accordance with such policies and procedures. 
  
 2. Reportable Events. 
  
 a. Definition of Reportable Event. For purposes of this CIA,
a “Reportable Event” means anything that involves: 
  
 i. a substantial Overpayment; or 
  
 ii. a matter that
a reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 22 

 A Reportable Event may be the result of an isolated event or a series of occurrences. 
  
 b. Reporting of Reportable Events. If Gambro determines
(after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Gambro shall notify OIG, in writing, within 30 days after making the determination that the
Reportable Event exists. The report to OIG shall include the following information: 
  
 i. If the Reportable Event results in an Overpayment, the report to OIG shall be made at the same time as the notification to the payor required in Section III.I.1, and shall include all of the information on the
Overpayment Refund Form, as well as: 
  
 A. the payor’s
name, address, and contact person to whom the Overpayment was sent; and 
  
 B. the date of the check and identification number (or electronic transaction number) by which the Overpayment was repaid/refunded; 
  
 ii. a complete description of the Reportable Event, including the relevant facts, persons involved, and legal and Federal
health care program authorities implicated; 
  
 iii. a
description of Gambro’s actions taken to correct the Reportable Event; and 
  
 iv. any further steps Gambro plans to take to address the Reportable Event and prevent it from recurring. 
  

	IV.	NEW BUSINESS UNITS OR LOCATIONS 

  
 In the event that, after the Effective Date, Gambro changes locations or
sells, closes, purchases, or establishes a new business unit or location related to the furnishing of outpatient dialysis, Gambro shall enter this information into a log as soon as possible, but no later than within 15 days after the date of change
of location, sale, closure, purchase, or establishment. Each log shall include the address of the new business unit or location, phone number, fax number, Medicare number, Gambro identification number and/or supplier number, the corresponding
contractor’s name and address that has issued each Medicare number, and the name, address, phone number, and provider and/or supplier number (if applicable) for each business partner of the new business unit or location. Each new business unit
or location shall be subject to all the requirements of this CIA. This log shall be made available to OIG upon request. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 23 

	V.	IMPLEMENTATION AND ANNUAL REPORTS 

  
 A. Implementation Report. Within 150 days after the Effective Date,
Gambro shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 
  
 1. the name, address, phone number, and position description
of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 
  
 2. the names and positions of the members of the Compliance Committee required by Section III.A; 
  
 3. a certification that each clinic has a CCL in place, as
required by Section III.A; 
  
 4. a copy of
Gambro’s Standards of Business Conduct required by Section III.B.1; 
  
 5. a copy of all Policies and Procedures required by Section III.B.2; 
  
 6. the number of individuals required to complete the Standards of Business Conduct certification required by Section III.B.1, the
percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG, upon request); 
  
 7. the following information regarding each type of training
required by Section III.C: 
  
 a. a description of such
training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; 
  
 b. number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. 
  
 A copy of all training materials and the documentation supporting this
information shall be available to OIG, upon request. 
  
 8. a description of the Disclosure Program required by Section III.F; 
  
 9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter;
(c) a summary and description of any and all current and prior engagements and agreements between Gambro and the IRO; and (d) the proposed start and completion dates of the Claims Review, Unallowable Cost Review, and Stat Labs Billing
Review. 
  
 10. a certification from the IRO
regarding its professional independence and/or objectivity with respect to Gambro; 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 24 

 11. a description of the process by which Gambro fulfills the requirements of
Section III.G regarding Ineligible Persons; 
  
 12. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.G; the actions taken in response to the screening and removal obligations set forth in Section III.G; and the
actions taken to identify, quantify, and repay any overpayments to Federal health care programs relating to items or services furnished, ordered, or prescribed by an Ineligible Person; 
  
 13. a list of all of Gambro’s locations (including locations and mailing addresses); the corresponding
name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare provider number(s), Gambro identification number(s), and/or supplier number(s); and the name and address of each
Medicare contractor to which Gambro currently submits claims; 
  
 14. a description of Gambro’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and 
  
 15. the certifications required by Section V.C.

  
 B. Annual Reports. Gambro shall submit to OIG annually
a report with respect to the status of, and findings regarding, Gambro’s compliance activities for each of the five Reporting Periods (Annual Report). 
  
 Each Annual Report shall include, at a minimum: 
  
 1. any change in the identity, position description, or other noncompliance job responsibilities of the Compliance Officer and any change
in the membership of the Compliance Committee described in Section III.A; 
  
 2. a certification that each clinic has its own CCL, as described in Section III.A; 
  
 3. a summary of any significant changes or amendments to the
Policies and Procedures required by Section III.B and the reasons for such changes (e.g., change in contractor policy) and copies of any compliance-related Policies and Procedures; 
  
 4. the number of individuals required to complete the
Standards of Business Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available
to OIG, upon request); 
  
 5. the following
information regarding each type of training required by Section III.C: 
  
 a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 25 

 b. number of individuals required to be trained, percentage of individuals actually trained, and an
explanation of any exceptions. 
  
 A copy of all training
materials and the documentation supporting this information shall be available to OIG, upon request. 
  
 6. a complete copy of all reports prepared pursuant to Section III.E, along with a copy of the IRO’s engagement letter;

  
 7. Gambro’s response and corrective
action plan(s) related to any issues raised by the reports prepared pursuant to Section III.E; 
  
 8. summary and description of any and all current and prior engagements and agreements between Gambro and the IRO, if different from what
was submitted as part of the Implementation Report; 
  
 9. a certification from the IRO regarding its professional independence and/or objectivity with respect to Gambro; 
  
 10. a summary of Reportable Events (as defined in Section III.I) identified during the Reporting Period and the status of any
corrective and preventative action relating to all such Reportable Events; 
  
 11. a report of the aggregate Overpayments that have been returned to the Federal health care programs. Overpayment amounts shall be broken down into the following categories: Medicare, Medicaid (report each
applicable state separately, if applicable), and other Federal health care programs. Overpayment amounts that are routinely reconciled or adjusted pursuant to policies and procedures established by the payor do not need to be included in this
aggregate Overpayment report; 
  
 12. a summary
of the disclosures in the disclosure log required by Section III.F that: (a) relate to Federal health care programs; or (b) allege abuse or neglect of patients; 
  
 13. any changes to the process by which Gambro fulfills the requirements of Section III.G regarding
Ineligible Persons; 
  
 14. the name, title, and
responsibilities of any person who is determined to be an Ineligible Person under Section III.G; the actions taken by Gambro in response to the screening and removal obligations set forth in Section III.G; and the actions taken to
identify, quantify, and repay any overpayments to Federal health care programs relating to items or services relating to items or services furnished, ordered or prescribed by an Ineligible Person; 
  
 15. a summary describing any ongoing investigation or legal
proceeding required to have been reported pursuant to Section III.H. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding;

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 26 

 16. a description of all changes to the most recently provided list of Gambro’s
locations (including addresses) as required by Section V.A.13; the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare provider number(s), Gambro
identification number(s), and/or supplier number(s); and the name and address of each Medicare contractor to which Gambro currently submits claims; and 
  
 17. the certifications required by Section V.C. 
  
 The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period.
Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report. 
  
 C. Certifications. The Implementation Report and Annual Reports shall include a certification by the Compliance Officer that: 
  
 1. to the best of his or her knowledge, except as otherwise
described in the applicable report, Gambro is in compliance with all of the requirements of this CIA; 
  
 2. he or she has reviewed the Report and has made reasonable inquiry regarding its content and believes that the information in the Report
is accurate and truthful; and 
  
 3. Gambro has
complied with its obligations under the Settlement Agreement: (a) not to resubmit to any Federal health care program payors any previously denied claims related to the Covered Conduct addressed in the Settlement Agreement, and not to appeal any
such denials of claims; (b) not to charge to or otherwise seek payment from federal or state payors for unallowable costs (as defined in the Settlement Agreement); and (c) to identify and adjust any past charges or claims for unallowable
costs; 
  
 D. Designation of Information. Gambro shall
clearly identify any portions of its submissions that it believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act
(FOIA), 5 U.S.C. §552. Gambro shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 27 

	VI.	NOTIFICATIONS AND SUBMISSION OF REPORTS

  
 Unless otherwise stated in writing after the
Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: 
  
 OIG: 
  
 Administrative and Civil Remedies Branch 
 Office of Counsel to the Inspector General 
 Office of Inspector General 
 U.S. Department of Health and Human Services 
 Cohen Building, Room 5527 
 330 Independence Avenue, S.W. 
 Washington, DC 2020 1 
 Telephone: (202) 619-2078 
 Facsimile: (202) 205-0604 
  
 Gambro: 
  
 Christopher J. Riopelle 
 Senior Vice President and Chief Compliance Officer 
 Gambro Healthcare, Inc. 
 10810 W. Collins Avenue 
 Lakewood, CO 80215 
 Telephone: (303) 542-5196 
 Facsimile: (303) 209-7615 
  
 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of
this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. 
  

	VII.	OIG INSPECTION, AUDIT, AND REVIEW RIGHTS

  
 In addition to any other rights OIG may have by
statute, regulation, or contract, OIG or its duly authorized representative(s) may examine or request copies of Gambro’s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Gambro’s
locations for the purpose of verifying and evaluating: (a) Gambro’s compliance with the terms of this CIA; and (b) Gambro’s compliance with the requirements of the Federal health care programs in which it participates. The
documentation described above shall be made available by Gambro to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized
representative(s) may interview any of Gambro’s employees, contractors, or agents who consent to be interviewed at the individual’s place of business during normal business hours or at such other place and time as may be mutually agreed
upon between the individual and OIG. Gambro shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. Gambro’s employees may elect to be interviewed with or
without a representative of Gambro present. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 28 

	VIII.	DOCUMENT AND RECORD RETENTION 

  
 Gambro shall maintain for inspection all documents and records relating to
reimbursement from the Federal health care programs, or to compliance with this CIA, for six years (or longer if otherwise required by law). 
  

	IX.	DISCLOSURES 

  
 Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Gambro prior to any release by OIG
of information submitted by Gambro pursuant to its obligations under this CIA and identified upon submission by Gambro as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With
respect to such releases, Gambro shall have the rights set forth at 45 C.F.R. § 5.65(d). 
  

	X.	BREACH AND DEFAULT PROVISIONS 

  
 Gambro is expected to fully and timely comply with all of its CIA
obligations. 
  
 A. Stipulated Penalties for Failure to Comply
with Certain Obligations. As a contractual remedy, Gambro and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as
“Stipulated Penalties”) in accordance with the following provisions. 
  
 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Gambro
fails to establish and implement any of the following obligations as described in Section III: 
  
 a. a Compliance Officer; 
  
 b. a Compliance Committee; 
  
 c. a written Standards of Business Conduct; 
  
 d. written Policies and Procedures; 
  
 e. the training of Covered Persons; 
  
 f. a Disclosure Program; 
  
 g. Ineligible Persons screening and removal requirements; and 
  
 h. Notification of Government investigations or legal proceedings. 
  
 2. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation
became due) for each day Gambro fails to engage an IRO, as required in Section III.E and Appendix C. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 29 

 3. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date
the obligation became due) for each day Gambro fails to submit the Implementation Report or the Annual Reports to OIG in accordance with the requirements of Section V by the deadlines for submission. 
  
 4. A Stipulated Penalty of $2,500 (which shall begin to
accrue on the day after the date the obligation became due) for each day Gambro fails to submit the annual Claims Review Report, the Unallowable Cost Review Report, the annual Stat Labs Billing Review Report, or the annual Heightened Arrangements
Review Report in accordance with the requirements of Sections III.D and E and Appendixes B, C, D, and E. 
  
 5. A Stipulated Penalty of $1,500 for each day Gambro fails to grant access to the information or documentation as required in
Section VII. (This Stipulated Penalty shall begin to accrue on the date Gambro fails to grant access.) 
  
 6. A Stipulated Penalty of $5,000 for each false certification submitted by or on behalf of Gambro as part of its Implementation Report,
Annual Report, additional documentation to a report (as requested by the OIG), or otherwise required by this CIA. 
  
 7. A Stipulated Penalty of $1,000 for each day Gambro fails to comply fully and adequately with any obligation of this CIA. OIG shall
provide notice to Gambro, stating the specific grounds for its determination that Gambro has failed to comply fully and adequately with the CIA obligation(s) at issue and steps Gambro shall take to comply with the CIA. (This Stipulated Penalty shall
begin to accrue 10 days after Gambro receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under
Subsections 1-6 of this Section. 
  
 B. Timely Written Requests
for Extensions. Gambro may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this CIA. Notwithstanding any other provision in this Section, if
OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Gambro fails to meet the
revised deadline set by OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until
three business days after Gambro receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a request in writing received by OIG at least five business days
prior to the date by which any act is due to be performed or any notification or report is due to be filed. 
  
 C. Payment of Stipulated Penalties. 
  
 1. Demand Letter. Upon a finding that Gambro has failed to comply with any of the obligations described in Section X.A and
after determining that Stipulated Penalties are appropriate, OIG shall notify Gambro of: (a) Gambro’s failure to comply; and (b) OIG’s exercise 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 30 

 
of its contractual right to demand payment of the Stipulated Penalties (this notification is referred to as the “Demand Letter”). 
  
 2. Response to Demand Letter. Within 10 days after
the receipt of the Demand Letter, Gambro shall either: (a) cure the breach to OIG’s satisfaction and pay the applicable Stipulated Penalties; or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG’s
determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Gambro elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until Gambro cures, to OIG’s
satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this CIA and shall be grounds for exclusion under
Section X.D. 
  
 3. Form of Payment.
Payment of the Stipulated Penalties shall be made by certified or cashier’s check, payable to: “Secretary of the Department of Health and Human Services,” and submitted to OIG at the address set forth in Section VI. 

 
 4. Independence from Material Breach
Determination. Except as set forth in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s decision that Gambro has materially breached this CIA, which decision
shall be made at OIG’s discretion and shall be governed by the provisions in Section X.D, below. 
  
 D. Exclusion for Material Breach of this CIA. 
  
 1. Definition of Material Breach. A material breach of this CIA means: 
  
 a. a failure by Gambro to report a Reportable Event, take corrective action,
and make the appropriate refunds, as required in Section III.I; 
  
 b. a repeated or flagrant violation of the obligations under this CIA, including, but not limited to, the obligations addressed in Section X.A; 
  

c. a failure to respond to a Demand Letter concerning the payment of Stipulated Penalties in accordance with Section X.C; or 
  
 d. a failure to engage and use an IRO in accordance with Section III.E.

  
 2. Notice of Material Breach and Intent to
Exclude. The parties agree that a material breach of this CIA by Gambro constitutes an independent basis for Gambro’s exclusion from participation in the Federal health care programs. Upon a determination by OIG that Gambro has materially
breached this CIA and that exclusion is the appropriate remedy, OIG shall notify Gambro of (a) Gambro’s material breach; and (b) OIG’s intent to exercise its contractual right to impose exclusion (this notification is hereinafter
referred to as the “Notice of Material Breach and Intent to Exclude”). 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 31 

 3. Opportunity to Cure. Gambro shall have 30 days from the date of receipt of the
Notice of Material Breach and Intent to Exclude to demonstrate to OIG’s satisfaction that: 
  
 a. Gambro is in compliance with the obligations of the CIA cited by OIG as being the basis for the material breach; 
  
 b. the alleged material breach has been cured; or 
  
 c. the alleged material breach cannot be cured within the 30-day period,
but that: (i) Gambro has begun to take action to cure the material breach; (ii) Gambro is pursuing such action with due diligence; and (iii) Gambro has provided to OIG a reasonable timetable for curing the material breach. 

 
 4. Exclusion Letter. If, at the conclusion of the
30-day period, Gambro fails to satisfy the requirements of Section X.D.3, OIG may exclude Gambro from participation in the Federal health care programs. OIG shall notify Gambro in writing of its determination to exclude Gambro (this letter
shall be referred to hereinafter as the “Exclusion Letter”). Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of Gambro’s receipt of the Exclusion
Letter. The exclusion shall have national effect and shall also apply to all other Federal procurement and nonprocurement programs. Reinstatement to program participation is not automatic. After the end of the period of exclusion, Gambro may apply
for reinstatement by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004. 
  
 E. Dispute Resolution 
  
 1. Review Rights. Upon OIG’s delivery to Gambro of its Demand Letter or of its Exclusion Letter, and as an agreed-upon
contractual remedy for the resolution of disputes arising under this CIA, Gambro shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the
Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS
Departmental Appeals Board (DAB), in a manner consistent with the provisions in 42 C.F.R. §§ 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made
within 10 days after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. 
  
 2. Stipulated Penalties Review. Notwithstanding any provision of Title 42 of the United States
Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Gambro was in full and timely compliance with the obligations of this CIA for which OIG
demands payment; and (b) the period of noncompliance. Gambro shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an adverse ALJ
decision related to Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders Gambro to pay Stipulated 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 32 

 
Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a decision unless Gambro requests review of the ALJ
decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues its decision. 
  
 3. Exclusion Review. Notwithstanding any provision of
Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be: 
  
 a. whether Gambro was in material breach of this CIA; 
  
 b. whether such breach was continuing on the date of the Exclusion Letter;
and 
  
 c. whether the alleged material breach could not have
been cured within the 30-day period, but that: (i) Gambro had begun to take action to cure the material breach within that period; (ii) Gambro has pursued and is pursuing such action with due diligence; and (iii) Gambro provided to
OIG within that period a reasonable timetable for curing the material breach and Gambro has followed the timetable. 
  
 For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision favorable to OIG, or, if the ALJ rules for Gambro, only after
a DAB decision in favor of OIG. Gambro’s election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to exclude Gambro upon the issuance of an ALJ’s decision in favor of OIG. If the ALJ sustains the
determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that Gambro may request review of the ALJ decision by the DAB. If the DAB finds in favor
of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Gambro shall waive its right to any notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the
DAB finds in favor of Gambro, Gambro shall be reinstated effective on the date of the original exclusion. 
  
 4. Finality of Decision. The review by an ALJ or the DAB provided for above shall not be considered to be an appeal right arising
under any statutes or regulations. Consequently, the parties to this CIA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be considered final for all purposes under this CIA. 
  

	XI.	EFFECTIVE AND BINDING AGREEMENT 

  
 Consistent with the provisions in the Settlement Agreement pursuant to which
this CIA is entered, and into which this CIA is incorporated, Gambro and OIG agree as follows: 
  
 A. This CIA shall be applicable only to those operations of Gambro that are subject to United States laws and regulations; 
  
 B. This CIA shall be binding on the successors, assigns, and transferees of Gambro; 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 33 

 C. This CIA shall become final and binding on the date the final signature is obtained on the CIA;

  
 D. Any modifications to this CIA shall be made with the prior
written consent of the parties to this CIA; 
  
 E. OIG may agree
to a suspension of Gambro’s obligations under the CIA in the event of Gambro’s cessation of participation in Federal health care programs. If Gambro withdraws from participation in Federal health care programs and is relieved of its CIA
obligations by OIG, Gambro shall notify OIG at least 30 days in advance of Gambro’s intent to reapply as a participating Gambro or supplier with any Federal health care program. Upon receipt of such notification, OIG shall evaluate whether the
CIA should be reactivated or modified; and 
  
 F. The undersigned
Gambro signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA. 
  
 ON BEHALF OF
GAMBRO HEALTHCARE, INC. 
  

					
			
	 /s/ Christopher J. Riopelle
	 	 	 	 11/29/04

	 CHRISTOPHER J. RIOPELLE
 Senior Vice President & Chief Compliance Officer
 Gambro Healthcare, Inc.
	 	 	 	 DATE

			
	 /s/ Judith A. Waltz
	 	 	 	 11/29/04

	 JUDITH A. WALTZ, ESQ.
 Foley & Lardner LLP
 Counsel for Gambro Healthcare, Inc.
	 	 	 	 DATE

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 34 

 ON BEHALF OF THE OFFICE
OF INSPECTOR GENERAL 
 OF THE DEPARTMENT
OF HEALTH AND HUMAN SERVICES. 
  

					
			
	 /s/ Lewis Morris
	 	 	 	 11/30/04

	 LEWIS MORRIS
 Chief Counsel to the Inspector General
 Office of Inspector General
 U.S. Department of Health and Human Services
	 	 	 	 DATE

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 35 

 GAMBRO HEALTHCARE, INC. CORPORATE
INTEGRITY AGREEMENT 
 APPENDIX A 
 INSTRUCTIONS FOR ARRANGEMENTS REVIEW 
  
 Gambro shall review and evaluate all Relevant Arrangements to ensure that each Relevant
Arrangement does not violate Anti-Kickback Statute. 
  

	A.	Relevant Arrangements consist of the following: 

  

	 	1.	All Arrangements with physicians; 

  

	 	2.	Lease Agreements with potential sources of patient referrals; 

  

	 	3.	Joint Ventures; 

  

	 	4.	Pharmaceutical Vendors; 

  

	 	5.	Stat Lab Agreements; 

  

	 	6.	Management Agreements; and 

  

	 	7.	Dialysis Transfer Agreements with nursing homes. 

  

	B.	Gambro shall create a database, which shall contain the information Gambro considers necessary to evaluate the Relevant Arrangement’s compliance with the Anti-Kickback Statute
including, at a minimum, the following: 

  

	 	1.	each party involved in the Arrangement (e.g., physician, Gambro subsidiary); 

  

	 	2.	the relationship(s) between or among the parties (e.g., physician employment contract, medical directorship, lease agreement); 

  

	 	3.	the term of the Arrangement, including start and expiration dates (including any automatic renewal provisions); 

  

	 	4.	the nature and material terms of the Arrangement, including the subject of the contract and type of service or supplies provided; 

  

	 	5.	the methodology for determining compensation, including fair market value, and the means by which compensation is paid (e.g., bonus, salary, services); and

  

	 	6.	potentially applicable safe harbor(s). 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix A 
 A-1 

 GAMBRO HEALTHCARE, INC. CORPORATE
INTEGRITY AGREEMENT 
 APPENDIX B 
 HEIGHTENED ARRANGEMENT REVIEW 
  

	I.	The Arrangement Samples 

  

	 	A.	Definitions 

  
 All terms defined in Gambro’s Corporate Integrity Agreement (CIA) and Appendix A retain their meaning for this Appendix. In addition, the
following terms are defined as follows. 
  
 1. Joint
Venture: For purposes of this CIA, a Joint Venture exists when Gambro owns less than 100% of a Gambro Clinic. 
  
 2. Population: the universe of Gambro Clinics from which a Sample Frame is formed. 
  
 3. Sample Frame: the portion of the Population from which a sample is drawn. 
  
 4. Sample Unit: a Gambro Clinic. 
  

	 	B.	Selecting the Samples. Gambro shall randomly select three different Arrangement Samples of Gambro Clinics. 

  
 1. The Arrangement Samples shall consist of the following. 
  

	 	a.	Joint Venture Sample 

  
 The Joint Venture Sample shall consist of 10 percent of the Sample Frame for the Joint Venture Sample. The Sample Frame for the Joint
Venture Sample shall consist of all Gambro Clinics for which Gambro has a Joint Venture agreement. 
  

	 	b.	Medical Director Sample 

  
 The Medical Director Sample shall consist of 10 percent of all Gambro Clinics. The Sample Frame for the Medical Director Sample shall
consist of all Gambro Clinics except those Gambro Clinics that have been selected as Sample Units in the Joint Venture Sample for the current Reporting Period. For the first Reporting Period, the Sample Units shall be ranked according to the dollar
value of their Medical Director compensation package and selected at random according to the following strata distribution. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix B 
 B-1 

				
	 Top 50 Clinics
	  	45	%
	 Next 100 Clinics
	  	45	%
	 Remaining 400
	  	10	%

  
 For each Reporting
Period after the first Reporting Period, Gambro shall formulate a work plan that describes how the Medical Director Samples shall be stratified. This work plan shall be submitted to OIG for approval within the first ninety days of the Reporting
Period. 
  

	 	c.	Other Relevant Arrangement Sample 

  
 The Other Relevant Arrangement Sample shall consist of 1.5 percent of all Gambro Clinics. The Sample Frame shall consist of all Gambro Clinics
except for those Gambro Clinics that have been selected as Sample Units in the Joint Venture and Medical Director Samples for the current Reporting Period. 
  
 2. Use of First Samples Drawn. For the purposes of all Arrangement Samples, the Gambro Clinics selected in each first sample (or first sample for
each strata in the case of the Medical Directors Sample) shall be used (i.e., it is not permissible to generate more than one list of random samples and then select one for use with any of the Arrangement Samples). 
  

	II.	The Heightened Review 

  
 For each Gambro Clinic selected as part of the Arrangement Samples, Gambro shall conduct a thorough investigation of all Relevant Arrangements entered
into by or on behalf of the Gambro Clinic to determine Gambro’s compliance with the Anti-Kickback Statute. This investigation shall not be limited to a review of the documents and shall include interviews of relevant persons (including
Contractors and outside parties) and any other means of gathering information Gambro deems necessary to determine the intentions of Gambro in negotiating, effectuating, maintaining, and, if applicable, ending the Relevant Arrangement and the means
by which Gambro fulfilled those intentions. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 B-2 

 GAMBRO HEALTHCARE, INC. CORPORATE
INTEGRITY AGREEMENT 
 APPENDIX C 
 INDEPENDENT REVIEW ORGANIZATION 
  
 This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the
CIA. 
  

	A.	IRO Engagement. 

  
 Gambro shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The
IRO shall conduct the review in a professionally independent and/or objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives written notice of the identity of the selected IRO, OIG will notify Gambro if the IRO is
unacceptable. Absent notification from OIG that the IRO is unacceptable, Gambro may continue to engage the IRO. 
  
 If Gambro engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, Gambro shall
submit the information identified in Section V.A.8 to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives written notice of the identity of the selected IRO, OIG will notify Gambro if the IRO is unacceptable. Absent
notification from OIG that the IRO is unacceptable, Gambro may continue to engage the IRO. 
  

	B.	IRO Qualifications. 

  
 The IRO shall: 
  
 1. assign
individuals to conduct the Claims Review, the Unallowable Cost Review, and the Stat Lab Billing Review engagements who have expertise in the billing, coding, reporting, and other requirements of the Medicare end-stage renal disease benefit and in
the general requirements of the Federal health care program(s) from which Gambro seeks reimbursement; 
  
 2. assign individuals to design and select the Claims Review sample who are knowledgeable about the appropriate statistical sampling techniques;

  
 3. assign individuals to conduct the coding review portions of
the Claims Review who have a nationally recognized coding certification (e.g., CCA, CCS, CCS-P, CPC, RRA, etc.) and who have maintained this certification (e.g., completed applicable continuing education requirements); 
  
 4. have sufficient staff and resources to conduct the reviews required by the
CIA on a timely basis. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix C 
 C-1 

	C.	IRO Responsibilities. 

  
 The IRO shall: 
  
 1. perform each Claim Review, the Unallowable Cost Review, and the Stat Lab Systems Review in accordance with the specific requirements of the CIA;

  
 2. follow all applicable Medicare rules and reimbursement
guidelines in making assessments in the Claims Review, and Stat Lab Systems Review; 
  
 3. if in doubt of the application of a particular Medicare policy or regulation, request clarification from the appropriate authority (e.g., fiscal intermediary or carrier); 
  
 4. respond to all OIG inquires in a prompt, objective, and factual manner;
and 
  
 5. prepare timely, clear, well-written reports that
include all the information required by Appendixes D and E. 
  

	D.	IRO Independence/Objectivity. 

  
 The IRO must perform all reviews in a professionally independent and/or objective fashion, as appropriate to the nature of the engagement, taking into
account any other business relationships or engagements that may exist between the IRO and Gambro. 
  

	E.	IRO Removal/Termination. 

  
 1. Provider. If Gambro terminates its IRO during the course of the engagement, Gambro must submit a notice explaining its reasons to OIG no later
than 30 days after termination. Gambro must engage a new IRO in accordance with Paragraph A of this Appendix. 
  
 2. OIG Removal of IRO. In the event OIG has reason to believe that the IRO does not possess the qualifications described in Paragraph B, is not
independent and/or objective as set forth in Paragraph D, or has failed to carry out its responsibilities as described in Paragraph C, OIG may, at its sole discretion, require Gambro to engage a new IRO in accordance with Paragraph A of this
Appendix. 
  
 Prior to requiring Gambro to engage a new IRO, OIG
shall notify Gambro of its intent to do so and provide a written explanation of why OIG believes such a step is necessary. To resolve any concerns raised by OIG, Gambro may request a meeting with Gambro Healthcare, Inc. 
  
 OIG to discuss any aspect of the IRO’s qualifications, independence or
performance of its responsibilities and to present additional information regarding these matters. Gambro shall provide any additional information as may be requested by OIG under this Paragraph in an expedited manner. OIG will attempt in good faith
to resolve any differences regarding the IRO with Gambro prior to requiring Gambro to terminate the IRO. However, the final determination as to whether or not to require Gambro to engage a new IRO shall be made at the sole discretion of OIG.

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix C 
 C-2 

 GAMBRO HEALTHCARE, INC. CORPORATE
INTEGRITY AGREEMENT 
 APPENDIX D 
 CLAIMS REVIEW 
  

	A.	Claims Review. 

  
 1. Definitions. For the purposes of the Claims Review, the terms defined in the CIA shall retain the same meanings here. In addition, the following
definitions shall be used: 
  
 a. Overpayment: The amount
of money Gambro has received in excess of the amount due and payable under any Federal health care program requirements. 
  
 b. Paid Claim: A code or line item submitted by and for which Gambro has received reimbursement from the Medicare program. 
  
 c. Population: The Population shall be defined as all Clinics.

  
 d. Sampling Frame: The Portion of the Population from
which the sample is drawn. The Sampling Frame shall consist of the top 10% of Clinics with the highest billings per patient for separately billable drugs and nonlaboratory diagnostic tests (e.g., electrocardiograms). 
  
 e. Sample Unit: The Sample Unit shall be a Beneficiary Paid claim.

  
 f. Error Rate: The Error Rate shall be the percentage
of net Overpayments identified in the sample. The net Overpayments shall be calculated by subtracting all underpayments identified in the sample from all gross Overpayments identified in the sample. (Note: Any potential cost settlements or other
supplemental payments should not be included in the net Overpayment calculation. Rather, only underpayments identified as part of the Discovery Sample shall be included as part of the net Overpayment calculation.) 
  
 The Error Rate is calculated by dividing the net Overpayment identified in
the sample by the total dollar amount associated with the Items in the sample. 
  
 2. Other Requirements. 
  
 a. Paid Claims without Supporting Documentation. For the purpose of appraising Paid Claims included in the Claims Review, any Paid Claim for which Gambro cannot produce documentation sufficient to support the Paid Claim shall be
considered an error and the total reimbursement received by Gambro for such Paid Claim shall be deemed an Overpayment. Replacement sampling is not permitted. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix D 
 D-1 

 b. Replacement Sampling. Considering the Sample Unit shall consist only of Paid Claims and that
Paid Claims with missing documentation cannot be replaced, there is no need to utilize alternate or replacement sampling units. 
  
 c. Use of First Samples Drawn. For the purposes of all samples (Discovery Sample(s) and Full Sample(s)) discussed in this Appendix, the Paid Claims
selected in each first sample shall be used (i.e., it is not permissible to generate more than one list of random samples and then select one for use with the Discovery Sample or Full Sample). 
  

	B.	Claims Review Report. The following information shall be included in the Claims Review Report for each Discovery Sample and Full Sample (if applicable).

  
 1. Claims Review Methodology. 

 
 a. Sampling Unit. A description of the Beneficiary Paid Claim as
that term is utilized for the Claims Review. 
  
 b. Claims
Review Population. A description of the Population subject to the Claims Review. 
  
 c. Claims Review Objective. A clear statement of the objective intended to be achieved by the Claims Review. 
  
 d. Sampling Frame. A description of the Sampling Frame, which is the portion of the Population from which the Discovery Sample and, if any, Full
Sample has been selected and an explanation of the methodology used to identify the Sampling Frame. 
  
 e. Source of Data. A description of the specific documentation relied upon by the IRO when performing the Claims Review (e.g., medical
records, physician orders, certificates of medical necessity, requisition forms, local medical review policies (including title and policy number), CMS program memoranda (including title and issuance number), Medicare carrier or intermediary manual
or bulletins (including issue and date), other policies, regulations, or directives). 
  
 f. Review Protocol. A narrative description of how the Claims Review was conducted and what was evaluated. 
  
 2. Statistical Sampling Documentation. 
  
 a. The number of Paid Claims appraised in the Discovery Sample and, if applicable, in the Full Sample. 
  
 b. A copy of the printout of the random numbers generated by the
“Random Numbers” function of the statistical sampling software used by the IRO. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix D 
 D-2 

 c. A copy of the statistical software printout(s) estimating how many Beneficiary Paid Claims are to be
included in the Full Sample, if applicable. 
  
 d. A description
or identification of the statistical sampling software package used to select the sample and determine the Full Sample size, if applicable. 
  
 3. Claims Review Findings. 
  
 a. Narrative Results. 
  
 i. A description of Gambro’s billing and coding system(s), including the identification, by position description, of the personnel involved in coding
and billing. 
  
 ii. A narrative explanation of the IRO’s
findings and supporting rationale (including reasons for errors, patterns noted, etc.) regarding the Claims Review, including the results of the Discovery Sample, and the results of the Full Sample (if any). 
  
 b. Quantitative Results. 
  
 i. Total number and percentage of instances in which the IRO determined that
the Paid Claims submitted by Gambro (Claim Submitted) differed from what should have been the correct claim (Correct Claim), regardless of the effect on the payment. 
  
 ii. Total number and percentage of instances in which the Claim Submitted differed from the Correct Claim and in which such
difference resulted in an Overpayment to Gambro. 
  
 iii. Total
dollar amount of all Overpayments in the sample. 
  
 iv. Total
dollar amount of Paid Claims included in the sample and the net Overpayment associated with the sample. 
  
 v. Error Rate in the sample. 
  
 vi. A spreadsheet of the Claims Review results that includes the following information for each Paid Claim appraised: Beneficiary health insurance claim
number, date of service, procedure code submitted, procedure code reimbursed, allowed amount reimbursed by payor, correct procedure code (as determined by the IRO), correct allowed amount (as determined by the IRO), dollar difference between allowed
amount reimbursed by payor and the correct allowed amount. (See Attachment 1 to this Appendix.) 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix D 
 D-3 

 4. Systems Review. Observations, findings, and recommendations on possible improvements to the
system(s) and process(es) that generated the Overpayment(s). 
  
 5. Credentials. The names and credentials of the individuals who: (1) designed the statistical sampling procedures and the review methodology utilized for the Claims Review; and (2) performed the Claims Review. 

 

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix D 
 D-4 

 Attachment 1 
  
 Claims Review Results 
  

																	
	 Federal
Health Care
Program
Billed

	 	 Bene HIC #

	 	 Date of
Service

	 	 Procedure
Code
Submitted

	 	 Procedure
Code
Reimbursed

	 	 Amount
Allowed
Reimbursed

	 	 Correct
Procedure
Code (IRO
determined)

	 	 Correct
Allowed Amt
Reimbursed
(IRO
determined)

	 	 Dollar
Difference
between Amt
Reimbursed
and Correct
Allowed Amt

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix D 
 D-5 

 GAMBRO HEALTHCARE, INC. CORPORATE
INTEGRITY AGREEMENT 
 APPENDIX E 
 STAT LAB SYSTEMS REVIEW 
  

	A.	Stat Lab Systems Review. 

  
 1. Definitions. For the purposes of the Stat Lab Systems Review, the terms defined in the CIA shall retain the same meanings here. In addition, the
following definitions shall be used: 
  
 a. Stat Lab Test:
A laboratory test that must be performed immediately or on an urgent basis, and which is performed by a non-Gambro lab. 
  
 b. Stat Lab Requisition: The form documenting the physician’s order for the Stat Lab test which is provided to the Stat Lab with the patient
specimen. 
  
 c. Population: The Population shall be
defined as all Gambro Clinics. 
  
 d. Sampling Frame: The
Portion of the Population from which the sample is drawn. The Gambro Clinics shall be ranked according to the number of Stat Lab Requisitions during the 12-month period under review. The Sampling Frame shall consist of 50 Gambro Clinics, in the
following strata: 
  

					
	Top 50 Clinics	 	20 Sampling Units	 	 
	Next 100 Clinics	 	20 Sampling Units	 	 
	Remaining 400	 	10 Sampling Units	 	 

  
 e. Sample
Unit: The Sample Unit shall be a Stat Lab Requisition. 
  
 f.
Stat Lab Files: Records associated with the Stat Lab Requisition including instructions for billing, test results, indication of billing by the Stat Lab to Gambro and Stat Lab agreements, where available. 
  
 g. Deficiency. Any Stat Lab Requisition for which Gambro cannot
produce Stat Lab Files in accordance with its policies and procedures. 
  
 2. Other Requirements. 
  
 a. Root Cause
Analysis. The root cause of any Deficiencies shall be identified, and a corrective action plan shall be implemented. 
  
 b. Replacement Sampling. Considering the Sample Unit shall consist only of Requisitions and that Requisitions with missing documentation cannot be
replaced, there is no need to utilize alternate or replacement-sampling units. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix E 
 E-1 

	B.	Stat Lab Systems Review Report. The following information shall be included in the Stat Lab Systems Review Report. 

  
 1. Stat Lab Systems Review Methodology. 
  
 a. Sampling Unit. A description of the Stat Lab Requisition as that
term is utilized for the Stat Lab Systems Review. 
  
 b. Stat
Lab Systems, Review Population. A description of the Population subject to the Stat Lab Systems Review. 
  
 c. Stat Lab Systems Review Objective. A clear statement of the objective intended to be achieved by the Stat Lab Systems Review. 
  
 d. Sampling Frame. A description of the Sampling Frame, which is the
portion of the Population from which the Sample has been selected and an explanation of the methodology used to identify the Sampling Frame. 
  
 e. Source of Data. A description of the specific documentation relied upon by the IRO when performing the Stat Lab Systems Review (e.g.,
requisitions, instructions for billing, resulting tests, indication of billing by the stat lab to Gambro, and applicable Gambro policies and procedures). 
  
 f. Review Protocol. A narrative description of how the Stat Lab Systems Review was conducted and what was evaluated. 
  
 2. Statistical Sampling Documentation. 
  
 a. The number of Stat Lab Requisitions appraised in the Sample. 

 
 b. A description or identification of the statistical sampling software
package used to select the sample. 
  
 3. Stat Lab Systems
Review Findings. 
  
 a. Narrative Results. 

 
 i. A description of Gambro’s Stat Lab Requisition process.

  
 ii. A summary of Gambro’s Stat Lab policy and
procedures. 
  
 iii. A narrative explanation of the IRO’s
findings and supporting rationale (including reasons for Deficiencies, patterns noted, etc.) regarding the Stat Lab Systems Review, including the results of the Sample. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix E 
 E-2 

 b. Quantitative Results. 
  
 i. Total number and percentage of instances in which the IRO determined Deficiencies. 
  
 ii. Observations, findings, recommendations, and corrective action plan on
possible improvements to the system(s) and process(es) that generated the Deficiencies (Root Cause Analysis). 
  
 4. Credentials. The names and credentials of the individuals who: (1) designed the statistical sampling procedures and the review methodology
utilized for the Claims Review; and (2) performed the Stat Lab Systems Review. 
  

 Gambro Healthcare, Inc. 
 Corporate Integrity Agreement 
 Appendix E 
 E-3 

 APPENDIX F 
  
 OVERPAYMENT REFUND 
  

					
	TO BE COMPLETED BY MEDICARE CONTRACTOR
			
	 Date: _______________________________________________
	 	Date of Deposit:	  	___________________
	
	 Contractor Deposit Control # _______________________________________________________________

		
	 Contractor Contact Name: ______________________________________________________
	  	Phone #: ____________
	
	 Contractor Address: __________________________________________________________________________

	
	 Contractor Fax: ______________________________________________________________________________

  

			
	TO BE COMPLETED BY PROVIDER/PHYSICIAN/SUPPLIER
	
	Please complete and forward to Medicare Contractor. This form, or a similar document containing the following information, should accompany every voluntary refund so that receipt
of check is properly recorded and applied.
	
	PROVIDER/PHYSICIAN/SUPPLIER/NAME ____________________________________________________
	
	ADDRESS ________________________________________________________________________________
		
	 PROVIDER/PHYSICIAN/SUPPLIER # ___________
	 	CHECK NUMBER # _________________________
		
	 CONTACT PERSON: _________________________
	 	PHONE # _____________    AMOUNT OF CHECK
	
	 $___________________________________    CHECK DATE ______________________

	
	REFUND INFORMATION
	
	For each claim, provide the following:
	
	Patient Name _________________________________________    HIC # _____________________________
	
	Medicare Claim Number ______________________________    Claim Amount Refunded $ ______________
	
	Reason Code for Claim Adjustment ________ (Select Reason Code from list below. Use one reason per claim)
	
	(Please list all claim numbers involved. Attach separate sheet, if necessary)
	
	 Note: If Specific Patient/HIC/Claim #/Claim Amount data not available for all claims due to Statistical Sampling, please
indicate methodology and formula used to determine amount and reason for overpayment: ___________________________________________________

	
	For Institutional Facilities Only:
	
	Cost Report Year(s) _____________________
	
	(If multiple cost report years are involved, provide a breakdown by amount and corresponding cost report year.)
	
	For OIG Reporting Requirements:
	
	Do you have a Corporate Integrity Agreement with
OIG?        Yes                            No
	
	Reason Codes:

  

					
	 Billing/Clerical Error
	 	 MSP/Other Payer Involvement
	 	 Miscellaneous

	01 – Corrected Date of Service	 	08 – MSP Group Health Plan	 	13 – Insufficient Documentation
	02 – Duplicate	 	Insurance	 	14 – Patient Enrolled in an HMO
	03 – Corrected CPT Code	 	 09 – MSP No Fault Insurance
	 	15 – Services Not Rendered
	04 – Not Our Patient(s)	 	10 – MSP Liability Insurance	 	16 – Medical Necessity
	05 – Modifier Added/Removed	 	 11 – MSP, Workers Comp.
	 	17 – Other (Please Specify)
	06 – Billed in Error	 	        (Including Black Lung)	 	 
	07 – Corrected CPT Code	 	12 – Veterans Administration

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]